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ABSTRACT 
Cancer is known as uncontrollable cell growth which results in the formation of 
tumours in the areas that are affected by the cancer. There are two types of tumours: 
benign and malignant. This study focus is on prostate cancer (PCa) as one of the most 
common cancers in men around the world. A previous study has reported that there 
were 27,132 new cases of cancer in South Africa in 2010. Out of those, 4652   were 
prostate cancer cases, which make it a considerable issue. The prostate is a gland that 
forms part of the male reproductive system. Prostate cancer is more apparent in men 
over the age of 65 years however it can be present in men of a lower age. However it 
is rare in men under 45 years of age. Prostate cancer start as a small group of cancer 
cells that can grow into a mature tumour. In the advanced stages, the tumour cells can 
spread to other tissue by metastases and can lead to death. Current diagnostic tools 
include Digital Rectal Examination (DRE), the Prostate-Specific Antigen test (PSA) 
ultra sound, and biopsy.  
These methods are not completely accurate and it is insensitive to diagnose all PCa 
cases. Subsequently, the need for a more accurate and sensitive method for diagnosis 
of the early stage of the disease is needed. Biomarkers have recently been identified 
as a viable option for early detection of diseases, for example, biological indicators 
such as DNA, RNA, protein and microRNAs (miRNAs). 
MicroRNAs are small regulatory RNA molecules that modulate the activity of 
specific messenger RNA (mRNA) targets and play important roles in a wide range of 
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physiologic and pathologic processes. Their main function is to regulate gene 
expression in a variety of manners, including translational repression, mRNA 
cleavage and deadenylation. MiRNAs are increasingly becoming recognized as 
powerful biomarkers for human diseases. The information potentially held by 
miRNAs, combined with the fact that they are stable in serum and plasma, has led to 
a rapidly growing interest in using miRNAs in blood or urine as diagnostic and 
prognostic biomarkers.  
In this study, the main aim was to identify novel miRNAs that can potentially detect 
PCa at its earliest stage as well as serve as prognostic biomarkers. 
Mature miRNAs that have been experimentally implicated in PCa were extracted 
from the EXIQON database with each miRNA‟s reference paper showing 
experimental evidence for their association with PCa. All mature miRNA sequences 
deposited into the miRBase database, were also collected as well. Duplications were 
removed using the CD-HIT programme which generated two datasets, first dataset 
included 150 miRNA sequences that are validated for their association to PCa and 
were used as the query dataset. The second dataset was generated from all miRNAs 
that were collected from miRBase which included 2477 miRNAs sequences which 
were used as a reference dataset. 
Both datasets were used in the CD-HIT and BLAST algorithms for a similarity search 
between them and the result obtained from CD-HT showed 12 clusters which 
included 16 miRNAs. From BLAST, 258 similarities were detected with only the 
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common result between the two algorithms selected for farther analysis. Text mining 
was performed on the 14 common miRNAs using three databases namely PhenomiR, 
Mircancer, and PubMed. A list of 5 five miRNAs were identified as potential 
biomarker candidates as none of these miRNAs showed any known link to PCa. 
In silico methods were used for target gene identification of these five miRNAs to 
validate the association of these miRNAs to PCa in the absence of experimental data 
for these miRNAs. Twelve genes were identified using TiGER, DAVID, and 
STRING databases. Pathway, prognostic, and expression analysis were performed on 
these 12 genes and 4 out of 12 showed involvement in known PCa pathways, 9 out of 
12 showed good prognostic value for differentiating high and low risk PCa patients 
whilst 8 out of the 12 genes showed differential expression between PCa tissue and 
normal tissue as well when compared with other cancer tissues. 
By performing in silico approaches in this study, a list of 5 miRNAs and their 12 
target genes were identified, which potentially could be used as diagnostic and 
prognostic biomarkers for the management of PCa.  
 
 
 
 
http://etd.uwc.ac.za/
vii 
 
KEYWORDS: Prostate cancer, diagnostic biomarker, prognostic biomarker, 
expression profiling, In silico, MiRNAs, Bioinformatics. 
 
  
http://etd.uwc.ac.za/
viii 
 
TABLE OF CONTENTS 
 
DECLARATION OF AUTHORSHIP .................................................................. i 
ACKNOWLEDGMENTS .................................................................................... ii 
DEDICATION ...................................................................................................... iii 
ABSTRACT .......................................................................................................... iv 
TABLE OF CONTENTS ................................................................................... viii 
LIST OF ABBREVIATIONS ........................................................................... xvi 
LIST OF FIGURES ............................................................................................ xx 
LIST OF TABLES ............................................................................................ xxiii 
CHAPTER 1 ............................................................................................................ 1 
1.1 Cancer .............................................................................................................. 1 
1.2 Genetics of Cancer .......................................................................................... 2 
1.2.1 Oncogenes ................................................................................................... 2 
1.2.2 Tumour suppressor genes (TSGs) ............................................................ 3 
1.3 Anatomy of the prostate ................................................................................. 4 
1.4 Incidences of Prostate Cancer ........................................................................ 5 
1.5 Stages of prostate cancer ................................................................................ 5 
1.6 Risk factors for prostate cancer ..................................................................... 7 
http://etd.uwc.ac.za/
ix 
 
1.6.1 Age .............................................................................................................. 7 
1.6.2 Family history ............................................................................................ 7 
1.6.3 Occupation ................................................................................................. 7 
1.7 Diagnostic methods for prostate cancer ........................................................ 8 
1.7.1 Prostate-specific antigen ........................................................................... 8 
1.7.2 Digital Rectal Examination (DRE) .......................................................... 8 
1.7.3 Prostate biopsy ........................................................................................... 9 
1.7.4 Computed tomography (CT) .................................................................... 9 
1.7.5 Magnetic Resonance Imaging (MRI) ....................................................... 9 
1.8 Treatment of prostate cancer ....................................................................... 10 
1.9 Cancer biomarkers........................................................................................ 10 
1.10 Classification of biomarkers ...................................................................... 11 
1.10.1. Diagnostic biomarkers ......................................................................... 11 
1.10.2. Prognostic biomarkers ......................................................................... 13 
1.10.3. Predictive biomarkers .......................................................................... 13 
1.11 MiRNAs and Cancer ................................................................................... 14 
1.12 Biogenesis of miRNAs ................................................................................. 15 
1.13 MiRNAs as regulators of gene expression ................................................ 20 
1.14 MiRNAs as oncomiRs and Tumour suppressors ..................................... 20 
http://etd.uwc.ac.za/
x 
 
1.15 Methodology for discovery of biomarkers ................................................ 21 
1.16 Bioinformatics ............................................................................................. 22 
1.17 In silico detection of novel biomarkers ..................................................... 22 
1.18 Aim and objective ........................................................................................ 24 
Chapter 2 ............................................................................................................. 25 
Identification of microRNAs as diagnostic and prognostic biomarkers for 
prostate cancer using an in silico approach ...................................................... 25 
2.1 Introduction ................................................................................................... 25 
2.2 In silico techniques for biomarker identification ....................................... 26 
2.3 Data and text mining databases ................................................................... 27 
2.3.1 Exiqon ....................................................................................................... 27 
2.3.2 PubMed .................................................................................................... 28 
2.3.3 MiRcancer ................................................................................................ 28 
2.3.4 MiRBase ................................................................................................... 28 
2.3.5 PhenomiR ................................................................................................. 29 
2.4 Local similarity tools for novel miRNA identification ............................... 29 
2.4.1 CD-HIT ..................................................................................................... 30 
2.4.2 Local BLAST ........................................................................................... 30 
2.5 Aim and objectives ........................................................................................ 31 
http://etd.uwc.ac.za/
xi 
 
2.6 Methodology .................................................................................................. 32 
2.6.1 Data extraction ........................................................................................ 33 
2.6.1.1 Data extraction from Exiqon ............................................................... 33 
2.6.1.2 Sequence extraction using MiRbase ................................................... 33 
2.6.1.3 Duplication removal ............................................................................. 33 
2.6.2. Identification of potential novel miRNAs for Prostate Cancer ............. 34 
2.6.2.1 Blast for similarity searches ................................................................ 34 
2.6.2.2 CD-HIT .................................................................................................... 35 
2.7 Results ............................................................................................................ 36 
2.7.1 Data extraction from Exiqon .................................................................. 36 
2.7.2 Sequence extraction using MiRBase ...................................................... 36 
2.7.2 Duplication removal ................................................................................ 37 
2.7.3 Identification of potential novel miRNAs for Prostate Cancer .............. 38 
2.7.3.1 BLAST for similarity searches ............................................................ 38 
2.7.3.2 CD-HIT .................................................................................................. 38 
2.8 Text mining .................................................................................................... 40 
2.9 Discussion ....................................................................................................... 43 
Chapter 3 ............................................................................................................. 46 
http://etd.uwc.ac.za/
xii 
 
Identification of target genes in prostate cancer for candidate miRNAs using 
an in silico approach ........................................................................................... 46 
3.1 Introduction ................................................................................................... 46 
3.2 Use of available databases for target gene identification .......................... 48 
3.2.1 Use of mirDIP microRNAs Data Integration Portal ............................ 48 
3.2.2 Tissue-specific Gene Expression and Regulation ................................. 51 
3.2.3 Intersection analysis by Venn diagrams ................................................ 52 
3.2.4 Functional characterisation of genes via DAVID ................................. 53 
3.2.5 Gene/protein interaction analysis via STRING .................................... 53 
3.2.6 KEGG pathway analysis ......................................................................... 54 
3.3 Aim and objectives ........................................................................................ 55 
3.4 Methodology .................................................................................................. 56 
3.4.1 Use of mirDIP microRNAs Data Integration Portal ............................ 57 
3.4.2 TiGER to extract prostate tissue expressed genes ................................ 57 
3.4.3 Intersection analysis by Venn diagrams ................................................ 57 
3.4.4 Involvement of genes in prostate cancer using the DAVID database . 58 
3.5 KEGG Pathway analysis of the genes in prostate cancer .......................... 58 
3.6 Analysis of Gene/protein interaction network ............................................ 59 
3.7 Results ............................................................................................................ 59 
http://etd.uwc.ac.za/
xiii 
 
3.7 .1 MirDIP miRNAs target gene prediction .............................................. 59 
3.7.2 TiGER database ...................................................................................... 60 
3.7.3 Venn diagram of intersectiing genes ...................................................... 61 
3.7.4 DAVID database result involving genes in prostate cancer ................ 61 
3.7.5 KEGG pathway analysis through DAVID database ............................ 62 
3.7.6 Gene interaction analysis using STRING database ............................. 65 
3.8 Discussion ....................................................................................................... 67 
Chapter 4 ............................................................................................................. 74 
Use of the identified miRNAs and their target genes as potential prognostic 
biomarkers for PCa using an in silico approaches ........................................... 74 
4.1 Introduction ................................................................................................... 74 
4.2 MiRNA as a prognostic biomarker ............................................................. 74 
4.3 Predictive biomarker .................................................................................... 75 
4.4 Using the available prognostic and expression databases. ........................ 76 
4.4.1 MiRNA prognostic databases ................................................................... 76 
4.4.1.1 PROGmiRV2 database ........................................................................ 76 
4.4.1.2 SurvMicro database ............................................................................. 76 
4.4.1.3 SurvExpress database .......................................................................... 77 
4.4.1.4 PrognoScan ........................................................................................... 78 
http://etd.uwc.ac.za/
xiv 
 
4.4.2 MiRNA and gene target expression databases ..................................... 78 
4.4.2.1 Database of differentially expressed miRNAs in human cancers 
(dbDEMC version 2.0) ..................................................................................... 78 
4.4.2.2 FIREBROWSE database for gene expression analysis .................... 80 
4.5 Aim and objectives ........................................................................................ 82 
4.6 Methods and Materials ................................................................................. 83 
4.6.1 Databases for miRNAs and target genes prognostic analysis ................ 83 
4.6.1.1 PROGmiRV2 ........................................................................................ 83 
4.6.1.2 SurvMicro database ............................................................................. 83 
4.6.1.3 SurvExpress database .......................................................................... 84 
4.6.1.4 PrognoScan ........................................................................................... 84 
4.6.2 Databases miRNAs and target genes expression analysis ...................... 84 
4.6.2.1 DbDEMC 2.0 miRNA expression analysis ......................................... 84 
4.6.2.2 FIREBROWSE database ..................................................................... 85 
4.7 Results ............................................................................................................ 85 
4.7.1 Databases for miRNA prognostic analysis ............................................ 85 
4.7.2 SurvExpress database ............................................................................. 86 
4.7.3 PrognoScan Results ................................................................................. 87 
4.7.4 Expression analysis of potential MiRNAs ............................................. 90 
http://etd.uwc.ac.za/
xv 
 
4.7.5 Result from FIREBROWES database .................................................. 90 
4.8 Discussion ....................................................................................................... 99 
Conclusion and future work ............................................................................. 104 
5.1 Introduction ................................................................................................. 104 
5.2 Chapter 2 ..................................................................................................... 105 
Identification of novel miRNAs involved in PCa ........................................... 105 
5.3 Chapter 3 ..................................................................................................... 106 
Identification of the miRNA target genes ....................................................... 106 
5.4 Chapter 4 ..................................................................................................... 107 
Prognostic and expression analysis of the miRNA target genes ................... 107 
5.5 Conclusion .................................................................................................... 108 
5.6 Future work ................................................................................................. 109 
Reference ............................................................................................................ 110 
 
http://etd.uwc.ac.za/
xvi 
 
LIST OF ABBREVIATIONS 
Abbreviation Full Name 
% Percentage 
> Greater than 
3' 3 prime end 
5' 5 prime end 
ADT Androgen Deprivation Therapy 
AFZ Anterior fibromuscular zone 
Ago Argonaute 
AMACR Alpha-Methylacyl-CoA Racemes 
AR Androgen Receptor  
BP Base Pair 
BRCA1 Breast cancer 1 
BRCA2 Breast cancer 2 
CA 15-3 Cancer antigen 15-3 
CRM Cis-Regulatory Module 
CT Computed Tomography 
CTNNB1 Catenin Beta 1 
CYP24A1 Cytochrome P450 Family 24 Subfamily A Member1 
CZ Central Zone 
DAVID Database for Annotation, Visualization and 
Integrated Discovery 
Db1 Database 1 
Db2 Database 2 
DGCR8 DiGeorge Syndrome Critical Region in gene 8 
DNA Deoxyribonucleic acid 
DRE Digital Rectal Examination 
ER Estrogen Receptor 
http://etd.uwc.ac.za/
xvii 
 
EST Expressed Sequence Tag  
EXP-5 Exportin-5 
exRNAs Extracellular RNAs 
FISH Fluorescence in situ hybridization 
GEO Gene Expression Omnibus 
HSP90AA1 
Heat Shock Protein 90 Alpha Family Class A 
Member 1 
Hr-HPV 
High-risk Human Papillomavirus 
IGF1 Insulin Like Growth Factor 1 
IGFBP3 Insulin Like Growth Factor Binding Protein 1 
IGFBP3 Insulin Like Growth Factor Binding Protein 3 
IHC Immunohistochemistry 
KEGG Kyoto Encyclopaedia of Genes and Genomes  
KLK2 Kallikrein Related Peptidase 2 
KLK3 Kallikrein Related Peptidase 3 
KLK4 Kallikrein Related Peptidase 4 
MicroRNA Micro Ribonucleic acid 
MirDIP microRNA Data Integration Portal 
MiRmine Human miRNA Expression Database 
MRI Magnetic Resonance Imaging 
mRNA Messenger ribonucleic acid 
MSP Maximal Segment Pair  
MYH11 Myosin Heavy chain 11 
NA Nucleic Acid 
NCBI National Centre for Biotechnology Information 
NCI National Cancer Institute 
NCOA2 Nuclear Receptor Coactivator 2 
NIH National Institutes of Health 
NKX3.1 Homeobox Protein 
NGS Next Generation Sequence. 
http://etd.uwc.ac.za/
xviii 
 
NLM National Library of Medicine  
OMIM Online Mendelian Inheritance in Man 
PC3 Prostate Cancer Cell line 
PCa Prostate Cancer 
PCR Polymerase Chain Reaction 
PEC Prostate Epithelial Cells 
PR Progesterone Receptor 
Pre-miRNA Precursor miRNA 
Pri-miRNA Primary miRNA 
PSA Prostate-Specific Antigen 
PTEN Phosphatase and Tensin homolog 
PTGS2 Prostaglandin-Endoperoxide Synthase 2 
PZ Peripheral Zone 
qRT-PCR Quantitative real-time polymerase chain reaction 
RISC RNA-induced silencing complex 
RLC RISC loading complex 
RNA Ribonucleic acid 
RNase Ribonuclease 
siRNA Small interfering RNA 
SKOV3 Ovarian carcinoma cell line  
SRD5A2 Steroid 5 Alpha-Reductase 2 
ssRNA Single-strand RNA 
STRING Search Tool for the Retrieval of Interacting 
Genes/Proteins  
SVM Support Vector Machine 
TCGA The Cancer Genome Atlas 
TF Transcription factor 
TFs Transcription factors 
TiGER Tissue-specific Gene Expression and Regulation 
http://etd.uwc.ac.za/
xix 
 
 
  
TIMP-1 Tissue Inhibitor of Metalloproteinase-1 
TMPRSS2 Transmembrane Protease, Serine 2 
TSG Tumour Suppressor Gene 
TZ Transition Zone 
W Word size 
API Application Programming Interface 
ULK1 Unc-51 Like Autophagy Activating Kinase 1 
http://etd.uwc.ac.za/
xx 
 
LIST OF FIGURES 
Chapter 1 
Figure 1.1: Number of zones in the prostate gland (adapted from  the National 
Cancer Institute 2017). .................................................................................................. 4 
Figure 1.2: Classification of PCa using the Stage Number Method (adapted from the 
National Cancer Institute, 2016). .................................................................................. 6 
Figure 1. 3: The animal miRNA synthesis pathway and fly factors are in the squares 
adapted from (Wahid et al., 2010). ............................................................................. 19 
Chapter 2 
Figure 2.1: Outline of the in silico methodology used for miRNAs identification. ... 32 
 
Chapter 3 
Figure 3.1: Outline of the in silico methodology for prioritising of the miRNA target 
genes. ........................................................................................................................... 56 
Figure 3.2: Venn diagrams for representing the number of intersecting genes for the 
four miRNA clusters. List A: target genes generated by mirDIP and List B: genes 
expressed in prostate tissue generated by TiGER. ...................................................... 61 
Figure 3.3: Shows the implication of 5 genes (AR, SRD5A2, IGF1, KLK3, and NKX3-
1) out of 12 genes in PCa pathways with the genes highlighted in red. Link for the 
graph can be obtained at 
http://etd.uwc.ac.za/
xxi 
 
(https://david.ncifcrf.gov/kegg.jsp?path=hsa05215$Prostate%20cancer&termId=5500
28904&source=kegg) .................................................................................................. 64 
Figure 3.4: Protein Network Visualization generated by STRING. The interactions of 
the 11 miRNA targeted genes clustered together. The genes are represented by the 
nodes and the different line colours represent the types of evidence for the interaction. 
Indicate the evidence and the colours. ........................................................................ 65 
Figure3.5: Interaction network between the genes and other genes of interest using 
STRING. The genes in the outlined box were associated with target genes with their 
evidence....................................................................................................................... 66 
Chapter 4 
Figure 4.1: Kaplan Meier plot for positive control miRNA generated by the 
PROGmiRV2 database ............................................................................................... 86 
Figure 4.2: Gene expression analysis of the microRNA target genes using 
SurvExpress. The result outputs are given as box plots showing the expression of the 
gene in low and high-risk groups. ............................................................................... 87 
Figure 4.3: Kaplan Meier plots for IGF1, KLK3, and KLK4, showing their levels of 
expression for the high risk groups in red and for the low risk groups in blue use the 
PrognoScan database. .................................................................................................. 89 
Figure 4.4: Show the expression of the AR gene in 37 cancers types with expression 
sorted from high to low. .............................................................................................. 93 
Figure 4.5: Show the expression of the IGF1 gene in 37 cancers types with 
expression sorted from high to low ............................................................................. 93 
http://etd.uwc.ac.za/
xxii 
 
Figure 4.6: Show the expression of KLK3 in 37 different cancer types sorted from 
high to low expression. ............................................................................................... 94 
Figure 4.7: Show the expression of KLK4 in 37 different cancer types sorted from 
high to low expression. ............................................................................................... 94 
Figure 4.8: Show the expression of KLK2 in 37different cancer types sorted from 
high to low expression. ............................................................................................... 95 
Figure 4.9: Show the expression of AMACR in 37 different tumour and normal 
tissues sorted from high to low expression. ................................................................ 95 
Figure 4.10: Show the expression of CYP24A1 in 37 different tumour and normal 
tissues sorted from high to low expression. ................................................................ 96 
Figure 4.11: Show the expression of MYH11 in 37 different tumour and normal 
tissues sorted from high to low expression. ................................................................ 96 
Figure 4.12: Show the expression of NKX3-1 in 37 different tumour and normal 
tissues sorted from high to low expression. ................................................................ 97 
Figure 4.13: Show the expression of PTGS2 in 37 different tumour and normal 
tissues sorted from high to low expression. ................................................................ 97 
Figure 4.14: Show the expression of SRD5A2 in 37 different tumour and normal 
tissues sorted from high to low expression. ................................................................ 98 
Figure 4. 15: Show the expression of TMPRSS2 in 37 different tumour and normal 
tissues sorted from high to low expression. ................................................................ 98 
 
 
http://etd.uwc.ac.za/
xxiii 
 
LIST OF TABLES 
 
Table 2.1: Number of sequences extracted from Exiqon and miRBase ..................... 37 
Table 2.2: The number of unique miRNA sequence before and after removal of 
duplicates using the CD-HIT program ........................................................................ 37 
Table 2.3: The numbers of miRNA clusters with their percentage of similarity as 
calculated by the CD-HIT and BLAST programs. (The highlighted entry indicates the 
PCa linked miRNA and the entry designated by the alphanumeric letters A, B and C 
its homologous sequence). .......................................................................................... 40 
Table 2.4: List of experimentally validated miRNAs and candidate miRNAs based on 
text mining .................................................................................................................. 42 
 
Table 3. 1: The number of target genes in each miRNA cluster and common target 
genes produced by mirDIP .......................................................................................... 60 
Table 3.2: Shows the number of genes expressed in prostate tissue as determined by 
TiGER. ........................................................................................................................ 60 
Table 3. 3: Number of genes from intersection submitted to DAVID. ...................... 62 
Table 3. 4: The list of gene names for each cluster annotated to PCa ........................ 62 
 
Tbale 4.1: List of abbreviation used in graphical result from the FIREBROWSE 
database ....................................................................................................................... 81 
 
http://etd.uwc.ac.za/
xxiv 
 
Table 5. 1: Show genes that are involved in PCa pathways, genes having prognostic 
value and genes that are expressed in prostate tumour tissue. .................................. 108 
http://etd.uwc.ac.za/
1 
 
CHAPTER 1 
 
Introduction 
1.1 Cancer 
Cancer is a disease that is known to affect a variety of tissues in the body such as 
bone marrow, brain, blood, prostate and skin. Cancer is known to be one of the 
most common diseases (DeSantis et al., 2016) with 1,685,210 new cancer cases 
reported every year resulting in 595,690 deaths, making cancer a major public 
health issue worldwide. Cancer is a state of uncontrolled cell growth in which 
cells divide continuously resulting in tumour formation. Moreover, cancer cells do 
not undergo programmed cell death, or apoptosis because of the resultant 
mutations within these cells. Furthermore, cancer cells can distort the immune 
system, which usually removes the dead cells and any abnormal cells from the 
body, whilst some cancer cells have the ability to hide from the immune 
surveillance (Mendes et al., 2016). However, not all the changes in tissues can be 
considered cancerous. When tissue changes, it can become cancerous if not 
treated (Mendes et al., 2016). A tumour is classified depending on its ability to 
spread from the tissue of origin to adjacent tissues namely: 
(I) A benign tumour is not cancerous and rarely life-threatening; it appears 
to grow slowly and does not have the ability to spread to other tissue. 
Usually, it is quite similar to healthy cells. When it grows larger it 
becomes uncomfortable or presses on other organs. 
http://etd.uwc.ac.za/
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(II) A malignant tumour is a type of a tumour where the cells become 
aggressive and can spread (metastasize) to adjacent tissues. Cancer is 
also classified according to the type of cell where it originates from: 
 i) Carcinomas; which is classified as cancer starting in the skin or in 
the tissue covering internal organs which includes adenocarcinoma, 
basal cell carcinoma and squamous cell carcinoma.  
ii) Sarcomas; are classified as cancer that starts in the supportive 
tissues, such as the cartilage, bone, muscle, fat, and blood vessels. 
iii) Leukemias; which is classified as cancer that is found in blood-
forming tissue such as the bone marrow and produces abnormal blood 
cells. 
iv) Lymphomas and spinal cord cancer; are classified as cancer, which 
affects the nervous system. 
1.2 Genetics of Cancer 
The most common cause of cancer is genetic change whether these are acquired 
mutations which are more common or germline mutations which are not common 
in cancer (Rizzolo et al., 2011; Wang et al., 2017). There are different types of 
genes involved in initiating cancer such as oncogenes and tumour suppressor gene 
(TSG). 
1.2.1 Oncogenes 
Proto-oncogenes are grope of genes that cause of normal cell become cancerous 
after they mutated (Chial et al., 2008). Proto-oncogenes‟ code for a protein whose 
function is mostly to stimulate cell division, prevent cell differentiation or to 
http://etd.uwc.ac.za/
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regulate programmed cell death (Casey, Baylot and Felsher, 2017). When proto-
oncogenes are affected by mutations, increasing the production of these proteins, 
unregulated cell division occurs, causing slowing of the cell differentiation rate 
and an increased inhibition of cell death. These changes to the cell cause them to 
become cancerous (American Cancer Society, 2014). Hyperactive oncogenes 
impart metabolic and growth-promoting advantages to malignant cells, affecting 
individuals differently. There is a growing concern in understanding the role of 
oncogenes and their activity in cancer to distinguish between the harmful and 
dormant tumour subtypes (Dasgupta, Vishwanatha and Srinidhi, 2012). 
1.2.2 Tumour suppressor genes (TSGs) 
Tumour suppressor genes regulate cell division by encoding proteins that are 
involved in cell proliferation and repair of DNA damage (Hinds and Weinberg, 
1994). Mutagenesis leads to their de-activation which impair the repair of DNA 
damage resulting in uncontrolled cell growth, which signals the start of tumour 
progression (Sherr, 2004). TSGs either functions in promoting apoptosis or in the 
regulation of the cell cycle (Abreu Velez and Howard, 2015). There are several 
TSGs linked to cancer such as Phosphatase and Tensin Homolog (PTEN) which is 
a tumour suppressor gene associated with to Prostate Cancer (PCa). PTEN is 
involved in pathway regulation of cell growth and division, which is usually 
uncontrolled in cancer (de la Rosa et al., 2017). BRCA1 and BRCA2 genes 
produce tumour suppressor proteins which aid in the repair of damaged DNA, 
mutations in these genes are linked to breast cancer (Silver and Livingston, 2012). 
http://etd.uwc.ac.za/
4 
 
1.3 Anatomy of the prostate 
The prostate is a gland that is part of the male reproductive system and located 
between the bladder and bottom of the pelvic cavity. The size and shape of the 
prostate are like a walnut, and muscle tissue. The prostate gland consists of four 
regions: The peripheral zone (PZ) and the central zone (CZ) together comprise 
<95 % of the prostate mass in the prostate of a healthy man. The rest of the 
prostate gland comprises a peri-urethral transition zone (TZ) and the anterior 
fibromuscular zone (AFZ) also known as the stroma and the peri-urethral 
glandular zone (Figure 1.1). The glandular tissue produces about 20 % of seminal 
fluid and contributes to the viscosity of the semen (Aumüller et al., 1990). 
 
Figure 1.1: Number of zones in the prostate gland (adapted from the National 
Cancer Institute 2017). 
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PCa is classified as an adenocarcinoma, or glandular cancer, that starts when 
normal semen-secreting prostate glandular cells mutate into cancer cells. The 
region of the prostate gland where an adenocarcinoma is most common is the PZ. 
Initially, small clumps of cancer cells remain confined to an otherwise healthy 
prostate gland, PCa often metastasizes to lymph nodes, bone, and other distant 
sites (Kyprianou, 1994). 
1.4 Incidences of Prostate Cancer 
In men, PCa is the most commonly occurring cancer and the second leading cause 
of death after lung cancer (Siegel, Naishadham and Jemal, 2012). However, 
recent statistics mentioned PCa to be the second most common cancer after skin 
cancers in men (American Cancer Society, 2016). In addition, one in seven men 
are diagnosed with PCa according to the American Cancer Society, 2016), 
whereas an estimated 241,740 men were diagnosed with PCa and about 28,170 
died of PCa in 2012  (Siegel, Naishadham and Jemal, 2012). Likewise, 161,360 
new cases and 26,730 deaths were observed in the year 2016 (American Cancer 
Society, 2016). African-American males have the highest incidence of PCa in the 
world (Siegel, Naishadham and Jemal, 2012). In South Africa in 2013, 6778 new 
cases of PCa was recorded and distributed among the four races as follows; 
Blacks 2708, Asians 169, Coloureds 792 and Whites 3114 cases (Ed and Cur, 
2016).  
1.5 Stages of prostate cancer 
There are different methods to classify the various stages of PCa, which all 
depend on how far the cancer has spread at the time of diagnosis. These stages are 
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of importance to assist doctors in prescribing a specific treatment for the patient 
(Tewari, 2013). The stages of PCa are shown in Figure 1.2. In Stage I, the cancer 
is found in the prostate and usually cannot be detected by digital rectal 
examination (DRE). At this stage, the cancer is difficult to be detected by the 
current diagnostic methods. In Stage II, the tumour has grown bigger and is still 
confined to the prostate. In Stage III, the tumour has broken through the prostate 
capsule and affects the adjacent tissue such as the seminal vesicles. In Stage IV, 
metastasis is taking place where a tumour is spreading to other tissues or organs, 
usually the lymph nodes, liver, and lungs (Chen et al., 2017). 
 
Figure 1.2: Classification of PCa using the Stage Number Method (adapted from 
the National Cancer Institute, 2016). 
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1.6 Risk factors for prostate cancer  
1.6.1 Age  
 In a previous study, it was reported that the incidences of PCa increase with age. 
Therefore, PCa is rare in men younger than 40 years of age. About six out of ten 
cases of PCa are found in men older than 65 years ( Cancer Research UK, 2013). 
In Another study, the incidence of PCa in men older than 65 years was reported to 
have dropped from 53 % in 1990 to 27.8 % in 1996 and remained stable 
thereafter, whilst the number of diagnosed patients younger than 65 increased 
from 18.6 % in 1991 to 40.7 % in 2000 (Stangelberger, Waldert and Djavan, 
2008). Older men tend to be diagnosed with an advanced-stage of the disease and 
are more likely to die from PCa than younger men (Bian and Hoffman, 2013). 
1.6.2 Family history  
Family history is significantly linked with PCa risk in epidemiologic study. 
Moreover, a history of other diseases and certain inherited genetic conditions 
increase the chances to be at risk for PCa (Helfand, 2016). 
1.6.3 Occupation 
Manufacturing workers that are exposed to high dose chemical substances are at 
risk for developing PCa, some occupations have also been observed to increase 
the risk of PCa such as metalworking, fire-fighters, rubber production, 
administrative and managerial occupations (Sauvé, Lavoué and Parent, 2016). 
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1.7 Diagnostic methods for prostate cancer  
1.7.1 Prostate-specific antigen  
The prostate-specific antigen (PSA) test is one of the diagnostic tools used to 
detect PCa. PSA is secreted by prostatic epithelial cells and increased 
concentrations are associated with prostatic disease including cancer. Most 
doctors consider a PSA level of 4.0 ng/ml and lower as normal, whilst for levels 
higher than 4.0 ng/ml, a prostate biopsy is recommended to determine the 
presence of PCa (Walsh, 2006). Measuring PSA levels is more accurate in 
detecting PCa than Digital Rectal Examination (DRE) or ultrasound, however, 
combining PSA and DRE provided better results along with an additional 
ultrasound in those patients with abnormal PSA and DRE results (Tadayon et al., 
2016). PSA is also used for screening men with PCa and is used as a marker for 
identifying recurring disease following to treatment. However, PSA-based 
screening is also associated with overdiagnosis and overtreatment (Loeb et al., 
2014). The limited specificity of PSA as a cancer biomarker is attributed to the 
fact that the PSA is synthesized by all prostate epithelial cells, whether normal, 
hyperplastic, or cancerous. Elevated serum PSA levels may reflect the presence of 
cancer or may be caused by benign prostatic hyperplasia (BPH), infection, and 
chronic inflammation (Faruq and Vecchione, 2015). 
1.7.2 Digital Rectal Examination (DRE) 
The DRE is a test used by urologists to detect evident changes in the prostate 
gland; however, this can only be done on tumours that are relatively large. 
Another limitation is that most cancers occurring in that part of the anatomy are 
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not accessible by DRE. Digital rectal examinations are not sensitive enough to 
detect the small-volume of tumours that are most amenable to cure (Walsh et al., 
2014). 
1.7.3 Prostate biopsy  
Prostate needle biopsy is used to diagnose PCa and to detect the size of a tumour. 
Not all prostate biopsies are effective, as a false-negative result is sometimes 
obtained, and the procedure has to be repeated if the PSA level is very high. This 
makes prostate biopsy insensitive as a diagnostic tool for PCa as well as  being 
invasive (Loeb et al., 2013). 
1.7.4 Computed tomography (CT)  
Computed tomography (CT) is not recommended for new diagnostic testing for 
PCa, particularly whilst the cancer is still confined to the prostate. However, once 
the cancer has spread or after treatment has commenced, this test can be used to 
see if cancer cells are still present (Picchio, Giovannini and Messa, 2011). 
1.7.5 Magnetic Resonance Imaging (MRI) 
Magnetic resonance imaging (MRI) can also detect PCa. MRI scans show detailed 
images of soft tissues in the body. MRI scans use radio waves and strong magnets 
as a substitute for x-rays. Gadolinium may be injected before the scan for better 
tissue picture details. MRI scans provides a clear picture of PCa and show if the 
cancer has spread outside the prostate into the seminal vesicles and other adjacent 
tissue. This can be very important in determining a patient's treatment options. An 
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MRI scan is not recommended for newly diagnosed PCa that are likely to be 
confined to the prostate (Dickinson et al., 2011). 
1.8 Treatment of prostate cancer  
Treatment depends on the age, stage and other medical conditions (Trewartha and 
Carter, 2013). There are several options to treat PCa, such as surgery, radiation 
therapy, and hormonal therapy. However, all the current therapy options for men 
with PCa are not effective enough and induce several side effects. Furthermore, 
after surgical ablation of progressive cancer, metastasised tumour cells continue 
to progress and this is a side effect associated with surgery. The radioactive rays 
and chemotherapeutic treatment also affects normal cells such as bone marrow 
function, and can lead to bone necrosis and lung fibrosis (Ghribi et al., 2015). 
Also, androgen deprivation therapy (ADT) is used for PCa treatment combined 
with radiation therapy, which is more beneficial for patients with metastatic stage 
cancer. Androgen hormones are essential for PCa cells to grow and reducing the 
level of these hormones, inhibit PCa growth (Perlmutter and Lepor, 2007). 
1.9 Cancer biomarkers 
A biomarker, which is a biological molecule, has been established as a medical 
diagnostic tool. Biomarkers from body fluids or tissue are used to diagnose a 
disease or discriminate between a normal and an abnormal condition. These 
molecules are affected by the presence of disease or a change within biological 
processes. Moreover, they could be an indicator of the body‟s response to 
treatment. Biomarkers can increase the quality of health early in the diagnosis and 
monitoring of the disease and also during treatment (Madu and Lu, 2010). 
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1.10 Classification of biomarkers 
Biomarkers are classified based on the sequence of events, from the onset of 
exposure to disease, detection as well as playing an essential role in providing 
some insight into the prognosis, disease progression and response to treatment 
(Manne, Srivastava and Srivastava, 2005). There are a variety of biomarkers 
available, which is utilised in experimental research and clinical settings. 
Biomarkers are grouped into different categories such as early detection, 
diagnostics, prognostics and predictive biomarkers, and can be DNA, RNA and 
protein-based (R Mayeux, 2004). Therefore, biomarkers are invaluable tools for 
cancer detection, diagnosis, a patient‟s prognosis and treatment selection. 
Biomarkers can also function in localising a tumour and determine its stage, 
subtype and response to therapy. Identification of such signatures in surrounding 
cells or at more distal and easily sampled sites of the body viz., cells in the mouth 
(instead of the lung) or urine (instead of the urinary tract) can also influence the 
management of cancer (Bhatt et al., 2010). A significant focus of clinical 
research, as evident in many publications, has been the discovery and validation 
of biomarkers with the primary aim of facilitating disease diagnosis (Bhatt et al., 
2010). 
1.10.1. Diagnostic biomarkers 
Diagnostic biomarkers are used to screen or detect specific types of cancer. These 
biomarkers may be assessed from tumour specimens. However, most diagnostic 
biomarker research is performed on serum or plasma. The ideal source material 
for biomarker analysis is the blood, because of easy sampling methods and being 
http://etd.uwc.ac.za/
12 
 
relatively cheap (Sanjay et al., 2015). The goal of diagnostic biomarkers would be 
to apply them in a disease-screening setting or in patients with suspected cancer, 
who are at higher risk of developing the disease (Kulasingam and Diamandis, 
2008). Simple diagnostic tests with one or two biomarkers or more complex tests 
can be developed through assaying novel or putative biomarkers. At the molecular 
level, such tests can provide faster and more accurate information-rich diagnostics 
for various diseases (Costa-Pinheiro et al., 2015).  
Biomarker-based tests can confirm the clinical diagnosis and may provide other 
information concerning prognosis and best treatment options. These diagnostic 
tests may enable identification of the disease or susceptibility to its early stages, 
before being diagnosed by other means. Opportunities for the prevention of 
disease progression or better disease management which lead to improved patient 
outcomes and a reduction in the direct and indirect costs of a disease are provided 
(Costa-Pinheiro et al., 2015). Improved diagnostics to detect cancer at an early 
stage, when it is curable with current methods would provide the most significant 
benefit to cancer patients. For most cancers, 5-10 years‟ survival often approaches 
90 % for cancers detected at an early stage, while it may drop to 10 % or less for 
cancers detected at a later stage (Hazelton and Luebeck, 2011). Thus screening to 
detect cancer early saves lives is well established. For instance, Pap smears 
significantly reduce mortality through the early detection of pre-neoplastic 
cervical cancer lesions. Moreover, the test is employed widely despite its 
significant inconvenience, unpleasantness, cost and requirement for clinical 
expertise (Aebersold et al., 2005). In some countries, high-risk human 
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papillomavirus (hr-HPV) are implemented as the primary cervical cancer 
screening method (Litjens et al., 2013). 
1.10.2. Prognostic biomarkers 
The role of prognostic biomarkers is to acquire knowledge about the natural 
history of the disease in terms of metastatic potential, the likelihood of tumour 
progression and the probability of patient survival independently of treatment. 
Prognostic biomarkers are relevant to cancer research for various reasons, such as 
when it is used to determine if the expression of a protein, gene or another 
molecule is directly correlated with an aggressive phenotype (Oldenhuis et al., 
2008). This may provide important information about the biology of the disease 
and which pathways are activated when the phenotype is more aggressive. 
Furthermore, from a clinical aspect, availability of validated strong and 
independent prognostic tumour markers may be used to stratify patients in 
randomised clinical trials aiming at evaluating the effect of diverse drugs 
(Kulasingam and Diamandis, 2008). Many prognostic biomarkers are linked to 
different cancers such as the Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) 
expression, which is related to the aggressive forms of multiple myelomas 
(Terpos et al., 2010). Expression of the progesterone receptor (PR) is associated 
with a better survival rate in breast cancer patients (Harris et al., 2007).   
1.10.3. Predictive biomarkers 
The function of predictive biomarkers is to determine in which subset of patients, 
with a particular disease, drug treatment will be more effective. A common 
clinical observation is that the same treatment may induce excellent responses in 
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some patients, while in others it will not have any effect. Ideally, after testing for 
a panel of the predictive biomarkers for different treatment regimens, one could 
administer the most effective drug only to those patients, who based on the results 
of the biomarker analysis, will benefit most likely from that specific treatment 
(Nalejska, Maczyńska and Lewandowska, 2014). Biomarkers can also be used to 
predict toxicity and be particularly valuable for choosing between drugs with the 
same activity, but with different toxicity profiles (Kulasingam and Diamandis, 
2008). In terms of the drug response, there are various predictive biomarkers in 
clinical use such as mutations within BRCA1 and BRCA2 genes. These mutations 
are used as predictive biomarkers to evaluating a patient with platinum-sensitive 
ovarian cancer and to identify patients likely to respond to Poly (ADP-ribose) 
polymerase (PARP) inhibitors (Ledermann et al., 2012). Traditionally, biomarker 
included proteins, DNA and RNA. However more recently there has been an 
increasing focus on miRNAs as potential cancer biomarker. 
1.11 MiRNAs and Cancer 
MicroRNAs are small non-coding RNAs, which regulates the expression of a 
gene that is used by the cells to produce protein. MiRNAs have important roles in 
different cellular processes such as  the development, proliferation and apoptosis 
(Davis and Hata, 2009). MiRNA could be a potential biomarker for diseases, 
which include PCa. In previous studies, irregular expression of miRNAs in PCa 
tissue and cell lines has been shown (Porkka et al., 2007). For instance, after 
examining the expression level of miR-145 in human PCa tissue samples, a 
significant difference between an adjacent normal cell and a cancerous region was 
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observed (Zaman et al., 2010). Overexpression of miRNA-145 in PC3 cells was 
also shown to lead to cell cycle constraints and increased apoptosis (Zaman et al., 
2010). 
1.12 Biogenesis of miRNAs  
A diversity of proteins are involved in the processing of miRNAs, with primary 
stages occurring inside the nucleus. The primary miRNA( pri-miRNA) is cleaved 
by a Pol II enzyme resulting in the formation of a precursor miRNA (pre-miRNA) 
by the release of a 60–70 nt (nucleotide) hairpin structure (Lee et al., 2002; Zeng 
and Cullen, 2003; Wahid et al., 2010). In figure 1.3 the processing step, this 
cleavage is catalysed by Drosha, which requires cofactors such as Pasha in 
Drosophila melanogaster or Caenorhabditis elegans or the human DiGeorge 
syndrome critical region gene 8 (DGCR8) (Lee et al., 2003; Han et al., 2004; 
Wahid et al., 2010). Drosha conjugates with either Pasha or DGCR8 forming a 
large microprocessor complex (Gregory et al., 2004; Han et al., 2004). In vivo 
studies showed that the DGCR8 gene is significant in developmental processes 
and is well-conserved (Wahid et al., 2010). The animal pri-miRNAs usually 
include 33 base pairs (bp) in the region of the stem-loop as well as a terminal 
loop, and a single-strand RNA (ssRNA) flanking fragment. The DGCR8 gene 
initiates the cutting by process interaction with the ssRNA section, to direct 
Drosha in completing the cleavage of pri-miRNA. The slicing of RNA duplexes 
occurs around 11 bp away from the ssRNA-stem loop junction, processing the 
pri-miRNA to the pre-miRNA with an overhanging 2 nt 3′ and 5′-phosphate group 
(Lee et al., 2003; Zeng and Cullen, 2005; Han et al., 2006). 
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The processed pre-miRNAs are further transported through nuclear pore 
complexes into the cytoplasm for maturation into miRNAs (Nakielny and 
Dreyfuss, 1999), which is mediated by RanGTP-dependent nuclear transport 
receptor exportin-5 (EXP5) (Bohnsack, Czaplinski and Gorlich, 2004; Lund et al., 
2004). In other studies evidence that pre-miRNA transport is initiated by the 
EXP5-based recognition of >14-bp double-stranded RNA (ds-RNA) stem-loop 
followed by a joint binding to both the pre-miRNA and the GTP-bound cofactor 
Ran inside the nucleus. The EXP5 bounded pre-miRNA is exported from the 
nucleus, with associated GTP hydrolysis resulting in the release of the pre-
miRNA as depicted in figure 1.3 (Gwizdek et al., 2003; Lund et al., 2004; Zeng 
and Cullen, 2004). 
The nuclear cleavage process by Drosha expresses one end of the mature miRNA. 
The pre-miRNA is discharged into the cytoplasm  using EXP5 and is 
consequently processed by an endonuclease cytoplasmic RNase III enzyme Dicer 
to generate a mature miRNA (Grishok et al., 2001; Knight, 2001). Dicer is an 
enzyme that specifically measures 22 nt from the pre-existing terminus of the pre-
miRNA and performs the cleavage of a miRNA strand. Dicer is a well-conserved 
enzyme which is present in nearly all eukaryotic organisms. Several organisms 
contain multiple types of Dicers; as in D. melanogaster which comprises Dicer-1 
and Dicer-2, each having distinctive roles. Dicer-1 is involved in the maturation 
of miRNA, while Dicer-2 is essential for siRNA maturation (Lee et al., 2004). 
Dicer interacts with other proteins such as the Argonaute (Ago) family proteins in 
a variety of organisms, RNAi deficient-4 in C. elegans, and X mental retardation 
1 in D. melanogaster (Carmell et al., 2002; Tabara et al., 2002). 
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In recent studies, it was observed that D. melanogaster Dicer-1 involves 
interaction partner Loquacious (LOQS; also known as R3D1), which comprises 
three dsRNA binding motifs for pre-miRNA processing (Förstemann et al., 2005; 
Saito et al., 2005). The human Dicer is coupled with two closely homologous 
proteins, protein kinase, interferon-inducible double-stranded RNA-dependent 
activator (PRKRA) and trans-activation response RNA-binding protein (TRBP) 
(Lee et al., 2006; Chendrimada et al., 2010). The Dicer-associated proteins 
contribute to the formation of the RNA-induced silencing complex, with little 
processing activity required (Lee et al., 2006; Chendrimada et al., 2010).  
The precise roles of these respective proteins have yet to be resolved. According 
to the current model, after the generation of an approximately 22 nt miRNA 
duplex by Dicer cleavage, the miRNA duplex is incorporated into an Ago family 
protein complex generating an effector complex. Mostly, one strand of the 
miRNA (passenger strand or miRNA) is degraded, whereas the other strand 
remains bound to Ago as mature miRNA (guide strand or miRNA). In a few 
cases, miRNA is loaded into the RNA-induced silencing complex (RISC) and 
therefore, remains functional. The thermodynamic stability of the two ends of the 
duplex may determine which strand is to be selected as shown in a few studies 
(Khvorova, Reynolds and Jayasena, 2003; Wahid et al., 2010). 
Dicer, in conjunction with other interacting proteins (TRBP and/or PACT in 
human and LOQS in fly) and Ago family proteins, contributes to RISC assembly 
by forming a RISC-loading complex (RLC) (Tomari, 2004; Maniataki and 
Mourelatos, 2005). The exact mechanism regarding the role of RLC in RNA 
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loading to Ago is not known. However, evidence suggests that after the processed 
miRNA duplexes are released from Dicer, the stable end of the miRNA duplex 
binds to interact with proteins in the RLC, and the unstable end associates with 
the Ago proteins (Liu, 2003; Tomari, 2004). The endo-nucleolytic enzyme 
activity of the Ago protein has been demonstrated to be responsible for the 
removal of the miRNA passenger strands (Diederichs and Haber, 2007). 
Most of the miRNAs contain mismatches in the middle, and some Ago proteins 
lack “slicer” activity, making the passenger strand of the miRNA resistant to 
cleavage. Evidence suggests that an RNA Helicase (yet to be identified) mediates 
the unwinding and removal of the unselected strand of the miRNA duplex. After 
loading, the miRNA guides the RISC to its target mRNA, which is silenced 
through degradation or translation repression (Jones-Rhoades, Bartel and Bartel, 
2006; Wahid et al., 2010). 
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Figure 1. 3: The animal miRNA synthesis pathway and fly factors are in the 
squares adapted from (Wahid et al., 2010). 
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1.13 MiRNAs as regulators of gene expression 
MicroRNAs regulate the expression of target genes and usually have their specific 
genes, sometimes they cohabitate with the introns or untranslated regions of genes 
that encode proteins (Barrett, Fletcher and Wilton, 2012). The regulation of gene 
expression by miRNAs, which has been proposed to be combinatorial, has 
different miRNAs acting together on a gene to regulate its precise level of 
expression during its development and in response to stimuli (Tomari and 
Zamore, 2005). Estimates of the average number of unique mRNAs that are 
targets for repression by a typical miRNA vary, depending on the estimation 
method (Thomson, Bracken and Goodall, 2011). MiRNA regulated involvement 
has been shown in malignant B-cell development, with chronic lymphocytic 
leukaemia being the first disease associated with deregulation of miRNAs as 
tumour suppressor genes (Musilova and Mraz, 2015). 
1.14 MiRNAs as oncomiRs and Tumour suppressors 
MiRNAs associated with cancer are known as oncomiRs, which play a role in the 
translation of mRNA to produce proteins that are involved in the regulation of the 
cell cycle, apoptosis, and necrosis. Certain oncomiRs have been linked to specific 
cancer such as mir-17-92, which may function as an oncogene and promote 
cancer development by negatively regulating tumour suppressor genes and/or 
genes that control cell differentiation or apoptosis (Zhang et al., 2007). Studies 
have shown that some miRNAs regulate cell proliferation and apoptotic processes 
that are important in cancer formation (Hammond, 2006). By using multiple 
molecular techniques, which included Northern blot analysis, real-time PCR, 
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miRNA microarray measuring up- or down-expression of specific miRNAs, it 
was found that several miRNAs were directly involved in human cancers, 
including lung, breast, brain, liver, colon cancer and leukaemia (Melo and 
Esteller, 2011). Some miRNAs may function as oncogenes or tumour suppressors 
(Rufino-Palomares et al., 2013). 
1.15 Methodology for discovery of biomarkers  
The survival rate of a disease relies on its early detection with the most 
challenging part in the early diagnosis of cancer being that most cases are 
diagnosed after cancer has almost fully developed (Chari et al., 2015). At present, 
many methods are proposed to facilitate early detection using body fluids which 
are easily obtainable. Thus, the treatment can be more effective at the early stage 
of the disease (Chari et al., 2015). More attention is being paid to identify 
biomarkers in the body fluids such as genomic biomarkers, which identifies 
changes in chromosomes, genes, and proteins (Novelli et al., 2008). The new 
technological advances in proteomics have shown capable initiatives in 
identifying novel biomarkers of many diseases to investigate and generate a large 
amounts of data (Ahram and Petricoin, 2008). Molecular profiling supported by 
the completion of the Human Genome Project and the development of 
biotechnological tools has revolutionised the exploration of disease biomarkers 
(Ahram and Petricoin, 2008). There are several diagnostic biomarkers for 
different types of cancers currently in clinical use which are based on different 
techniques such as FISH for intense Vysis®Urovysion biomarker for bladder 
cancer, cologuard® biomarker for colorectal cancer using PCR and 
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BRACAnalysis CDx® biomarker for ovarian cancer using the PCR technique 
(Goossens et al., 2015). 
The use of Computational Biology (Bioinformatics) methods showed significant 
results in biomarker discovery, using machine learning techniques such as 
clustering and support vector machine (SVM) (Yousef et al., 2014). 
1.16 Bioinformatics 
Bioinformatics is an interdisciplinary field which involves conceptualisation of 
biology regarding  molecules and applying information techniques such as applied 
mathematics, computer science, and statistics to understand and organise the 
large-scale data generated from experimental techniques (Luscombe, Greenbaum 
and Gerstein, 2001). Bioinformatics further involves sub-categories which include 
the analysis of genomic, proteomic and phylogenetic data, facilitating medical 
research through enhancing the sophistication of diagnosis and drug design 
(Luscombe, Greenbaum and Gerstein, 2001). Furthermore, an array of 
bioinformatics tools have been developed for the analysis of available gene 
datasets to identify biomarkers for the diagnosis and prognosis of diseases (Phan 
et al., 2009). 
1.17 In silico detection of novel biomarkers  
In recent decades, bioinformatics has shown high accuracy in biological data 
analysis for the molecular biology field. Data analysis can be performed on 
different biological data such as protein, DNA, and RNA to evaluate their genetic 
changes, their expression in the human body and their involvement in diseases 
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such as cancer, cardiovascular disease, and osteoporosis etc (Zicari, 2014) In 
silico methods offer a less labourious, time consuming and cost-effective strategy 
over conventional methods of biomarker discovery. Through the use of in silico 
methods, a priority list of biomarkers can be generated to be validated 
experimentally. A previous study has successfully shown the use of in silico 
methods to identify 48 tissue specific proteins for colon, lung, prostate, and 
pancreas as potential cancer biomarkers. However, 14 out of these 48 proteins 
were well established in other studies as cancer or benign disease serum 
biomarkers (Prassas et al., 2012). As well in silico approach used for another 
disease, a combination of  in silico prediction and microarray analyses, 
successfully identified miR-4487 and miR-595 targeting ULK1 with experimental 
verification of this targeting, this could provide the basis to explore ULK1 and its 
target miRNAs as potential biomarkers in the future as a Parkinson‟s disease 
therapy (Chen et al., 2015). 
  
 
http://etd.uwc.ac.za/
24 
 
1.18 Aim and objective 
The general aim of this study is to identify novel microRNA(s) as biomarkers for 
early detection of PCa  
I)  Identify novel miRNAs as diagnostic and prognostic biomarkers for 
PCa using an in silico approach; 
II)  Identify the target genes for the identified miRNAs and demonstrate 
their involvement in PCa using in silico approaches; 
III) Determine the prognostic value of the identified miRNAs as well as 
their target genes using several in silico methods; and  
IV) Perform an expression analysis of the identified miRNAs and their 
target genes in prostate tissue versus other normal and cancerous 
tissues using in silico analysis. 
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Chapter 2  
Identification of microRNAs as diagnostic and prognostic biomarkers for 
prostate cancer using an in silico approach 
2.1 Introduction 
Prostate cancer (PCa) is one of the most common diseases in the world and a 
leading cause of death as a consequence of the shortcomings of current diagnostic 
methods since most PCa cases are diagnosed at the advanced stages (Sharma, 
Zapatero-Rodríguez and O‟Kennedy, 2017). Currently, physicians rely on the 
PSA test which is not completely accurate in determining the presence of PCa or 
other prostatic diseases, which then require additional diagnostic procedures and 
becomes highly costly for the patient. Current research is focusing on the use of 
molecular signatures for diagnostic purposes. Based on their change in expression, 
miRNAs has been suggested as potential biomarkers for use in diagnostics for 
different types of cancers (Fredsøe et al., 2017).  
MiRNAs functions in many different systems through regulation of their target 
genes (Bartel, 2004). The change in the expression of miRNAs affects the 
regulation of genes which are translated into proteins involved in cell proliferation 
and other cancer-related pathways (Johnson et al., 2007). MiRNAs have been 
known to be involved in a variety of human cancers such as the over-expression 
of miR-22, which is a primary growth-associated miRNA that leads to inhibition 
of growth in the ovarian carcinoma cell line (SKOV3) (Lenkala et al., 2014). 
However, proteomic and microarray studies revealed that miRNA mediated 
changes in protein expression usually results in altered mRNA expression, 
signifying that mRNA degradation is the major component of the repression 
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associated with mammalian miRNAs (Baek et al., 2008; Selbach et al., 2008). In 
most studies the involvement of miRNAs in the negative regulation of gene 
expression by base-pairing to the 3' UTR as well as up-regulating their target 
mRNA translation have been suggested (Vasudevan, Tong and Steitz, 2007). 
Literature studies suggest that miRNAs can serve as diagnostic biomarkers for a 
variety of cancers and is easily accessible from a variety of body fluids (Larrea et 
al., 2016). Therefore, there is a need to investigate the hidden functionalities of 
miRNAs as well as their target genes to make them suitable candidates for cancer 
diagnostics. 
The study of miRNA functional similarity is a significant parameter used to 
perform disease miRNA prioritisation, miRNA functional prediction, miRNA 
synergism identification as well as miRNA clustering (Teng et al., 2013). 
Sequence analysis is often used to infer functional and structural features of DNA, 
RNA as well as peptides (Durbin et al., 1998). A variety of tools are available to 
perform sequence analysis to understand the function of a miRNA. One of which 
is to perform similarity studies between experimentally validated miRNA 
sequences and the total number of deposited miRNAs in various databases, using 
a variety of in silico discovery tools which can lead to the identification of 
miRNAs not previously associated with a particular process or function. 
2.2 In silico techniques for biomarker identification  
In silico technologies aim to facilitate advances in medical science such as 
biomarker and drug discovery (Terstappen and Reggiani, 2001; Yu, 2009). In 
silico refers to analysis or experimentation carried out in a computer environment, 
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rather than in vitro or in vivo given the increasing amount of genetic and 
molecular data available. Computational models are used as virtual laboratories to 
test hypotheses rapidly and to prioritise empirical research. These methods have 
been employed in various studies for the rapid identification of diagnostic, 
prognostic and predictive biomarkers, such as genes, proteins and miRNAs, for 
different types of cancer in past decades (Lin and Wooley, 2005). 
2.3 Data and text mining databases 
A variety of databases were used for data mining and text mining purposes in this 
study to obtain the required information, with each database employed fully 
explained in the subsequent sections. 
2.3.1 Exiqon 
Exiqon houses various databases which include miRsearch 3.0, an online search 
tool freely available at https://www.exiqon.com/mirsearch. This tool quickly finds 
and displays specific miRNAs relevant to specific research with detailed 
information about each miRNAs. With the help of a miRNA name the following 
variables can be searched: a) miRBase history b) regulation of genes c) potentially 
co-transcribed microRNAs, d) disease in which the miRNA has been shown to be 
regulated and e) tissue/samples in which the miRNA has been found. 
Furthermore, validated targets as well as disease and tissue/sample information, is 
supported by references with a link to PubMed (Exiqon, n.d). 
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2.3.2 PubMed  
PubMed database available at https://www.ncbi.nlm.nih.gov/pubmed is a free 
search engine frequently used by academic researchers for different purposes first 
released in 1996. The United States National Library of Medicine (NLM) at 
the National Institutes of Health (NIH)  maintains the database as part of 
the Entrez system of information retrieval (Reyes-Aldasoro, 2017). For this study 
the PubMed database was used as a text mining tool.  
2.3.3 MiRcancer 
Text mining in MiRcancer available at http://mircancer.ecu.edu/ is based on 75 
constructed rules, which represent the common sentence structures typically used 
to state microRNA expression in cancers. The microRNA-cancer association 
database, miRCancer, is regularly updated by running a text mining algorithm 
against PubMed. All miRNA-cancer associations are confirmed manually after 
automatic extraction. miRCancer currently documents 878 relationships between 
236 microRNAs and 79 human cancers through the processing of >26 000 
published articles (Xie et al., 2013). 
2.3.4 MiRBase 
The primary miRNA sequence repository miRBase http://www.mirbase.org/ first 
released in 2002 contains 218 miRNA loci from five species the latest miRBase 
release (v20, June 2013) contains 24 521 miRNA loci from 206 species, processed 
to produce 30 424 mature miRNA products. The rate of deposition of novel 
microRNAs and the number of researchers involved in their discovery continue to 
increase, driven largely by small RNA deep sequencing experiments. MiRbase 
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also provides the role of nomenclature assignment for the novel miRNAs 
identified by the different research groups (Griffiths-Jones et al., 2006). 
2.3.5 PhenomiR 
In recent years, published in the scientific literature deregulation of miRNA 
expression in diseases and other biological processes have been investigated 
PhenomiR (http://mips.helmholtz-muenchen.de/phenomir/) provides a repository 
that offers all the scattered information about miRNA expression in a structured 
and uniform format. This allows users to perform individual queries for specific 
miRNAs and diseases as well as to use the complete dataset for large-scale 
statistical analyses. All information in PhenomiR is extracted from published 
experiments and has been manually curated. The literature reference for each 
database entry is annotated as a PubMed identifier and is hyperlinked to the 
PubMed database. Every individual entry of the database refers to an instance of a 
publication describing a specific disease or bioprocess. Presently, PhenomiR 
documents data from 296 articles that describe 542 studies. This dataset contains 
11,029 data points, each representing one deregulated miRNA in an experiment. 
A design principle of PhenomiR is to use well-established ontologies and 
resources (Ruepp et al., 2010). 
2.4 Local similarity tools for novel miRNA identification 
The following sections will focus on different similarity tools for identification of 
new miRNAs for PCa based on their similarity to experimentally validated 
miRNAs. 
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2.4.1 CD-HIT 
CD-HIT performs a very fast clustering of a large dataset of biological sequences 
which enhances the performance of sequence analysis as well as reduce the 
redundancy of sequences (Fu et al., 2012). In response to next-generation 
sequencing based accumulation of biological sequence data, a new CD-HIT 
program was developed which was accelerated with a novel core parallelisation 
approach as well as statistical techniques for efficient clustering of the respective 
datasets (Fu et al., 2012). The algorithm behind CD-HIT is short-word filtering, 
which can determine that the similarity between two sequences is below a certain 
value without performing an actual sequence alignment. This algorithm is not 
limited to protein sequence clustering; it can also be used for different analyses 
that involve a large number of sequence comparisons (Li and Godzik, 2006). 
2.4.2 Local BLAST 
BLAST is a heuristics method for fast sequence comparison, which precisely 
evaluates alignments that improve the measurement of local similarity along with 
the maximal segment pair (MSP) score which refers to a segment pair whose 
alignment score (without spaces) cannot be improved by extending it or 
shortening it. The performance of BLAST, as well as the alignments it generates, 
are analysed using the mathematical outputs of the stochastic properties of MSP 
scores. BLAST robustly perform biological sequence database searching, gene 
identification searches, motif searches, as well as analyse multiple similarity 
regions in a long biological sequence (Altschul et al., 1990). The two most 
considered parameters in BLAST similarity searches are: a) E-value which can be 
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any positive number, with the default being 10, and can be adjusted up to 100 for 
a desirable limit of output, and b) Word size (W), which should be an integer 
number; the default for proteins 3 could be changed to 2 to increase sensitivity. 
For  nucleotide sequences, a word size of 11 , is allowed, with the lowest word 
size being 7 (Koonin and Galperin, 2003). 
2.5 Aim and objectives  
The aim of this chapter is to identify miRNAs as diagnostic and prognostic 
biomarkers for PCa using a combination of data and text mining databases as well 
as sequence similarity tools to: 
I. Generate a list of mature miRNAs that are involved in PCa using the 
Exiqon database; 
II. Collect  all the mature miRNA sequences using miRBase; 
III. Search for miRNA similarity between the miRNA list generated from 
Exiqon and that generated by miRBase using the CD-HIT and BLAST 
programs; and 
IV. Finalise a list of potential miRNAs for further validation that can serve as 
diagnostic and prognostic biomarkers for PCa. 
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2.6 Methodology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Outline of the in silico methodology used for miRNAs identification. 
Data mining and retrieval 
Exiqon PCa mature miRNAs MiRBase all mature miRNAs 
Remove duplications using the 
CD-HIT program 
Remove duplications using the 
CD-HIT program 
List of mature miRNAs as 
reference dataset 
List of miRNAs linked to PCa as 
query dataset   
List of miRNAs as suitable candidates resulting from the analysis 
using local BLAST and CD-HIT 
Text mining to identify miRNAs without any link to PCa 
Use of CD-HIT for sequence 
similarity between the query and 
reference datasets    
Local BLAST to find similarity 
between the query dataset and 
reference dataset 
Finalise list of candidate miRNAs   
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2.6.1 Data extraction 
2.6.1.1 Data extraction from Exiqon  
Exiqon is one of the databases that provide information regarding experimentally 
validated miRNA as well as their involvement in disease such as cancer. In this 
study, Exiqon was used to collect all miRNA linked to PCa. The Exiqon database 
was accessed at https://www.exiqon.com/mirsearch and the keywords “prostate 
cancer” was used as input in the query option. The search option was then 
selected. The list of output miRNAs was saved for further analysis. 
2.6.1.2 Sequence extraction using MiRbase 
MiRBase was used to download all mature Homo sapiens miRNA sequences that 
are available to date using the link (http://mirbase.org/cgi-
bin/mirna_summary.pl?org=hsa). All mature miRNAs sequences were saved in 
text file fasta format for further analysis. The advantage of miRbase is that it 
provides the sequence precursor as well as the mature sequences. For this study, 
only mature miRNAs were used as this part of the miRNA performs its 
function(s). 
2.6.1.3 Duplication removal  
The CD-HIT program has an option that allows the user to remove duplications 
from a list of sequences, known as CD-HIT-454 and the re-engineered option CD-
HIT-EST. The duplicates in sequence are identified using criteria such as “(1) 
beginning at the same position, (2) having different lengths, with the short 
sequence fully aligned with the longer sequence, (3) having a 4 % mismatch 
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(insertions, deletions, and substitutions) and (4) having only 1 base per insertion 
or deletion where criteria three (3) and four (4) can be adjusted by the user. 
Mismatches are allowed in order to tolerate sequencing errors. The CD-HIT 
program was used to remove duplications from the two files. The first file 
containing the miRNA sequences involved in PCa used as the query dataset and 
the second file containing all mature miRNA sequences used as the reference 
dataset in this study. This program was used by running the basic command line 
below: 
Cd-hit-est      -i prostatemiRNA.fa     -o resultprostatemiRNA1    -c 0.95    -n 8. (1) 
Where –i is input filename in fasta format, -o is output filename, - c is sequence 
identity threshold, and -n is word length. 
 
 
2.6.2. Identification of potential novel miRNAs for Prostate Cancer 
2.6.2.1 Blast for similarity searches 
The BLAST program can be used to generate a database of the information of 
interest. This option was used to first build a database for all the Homo sapiens 
mature miRNAs extracted from MiRBase after removal of duplication to use as 
the reference set in this study using the command line below: 
Makeblastdb       –in    resultallmiRNA.fasta   -Parse_seqids –dbtypenucl……..(2) 
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Where – in is the input file, -Parse_seqids is sequence id parsing  and  –
dbtypenucl is specifing the input, with the molecule type for this work specifed as 
nucleotide.  
After creating the database containing all the mature miRNAs, the validated 
miRNAs for PCa was scanned against the database to identify the number of 
mismatches between the query dataset (validated miRNAs for PCa) and the 
reference dataset sequences of all known miRNAs). The number of mismatches 
allowed was three sequences with less than three mismatches having more than 90 
% similarity. The command line used to run the program was: 
Blastn –db allmiRNA.fasta - evalue 1e-3 - word_size 7 –query 
resultprostatemiRNA1.fa –out result with 1e-3.out …………………………… (3) 
There are four inputs specified with one output generated: -db which is the 
database generated by previous command line (2), - evalue specified as 1e-3, - 
word_size is the similarity region, -query is the query file, and –out is the the 
result file name. 
2.6.2.2 CD-HIT   
CD-HIT-EST-2D works on nucleotide sequences. One of the characteristics of 
CD-HIT-EST-2D is to compare two nucleotide datasets (db1, db2). Db1 contained 
the non-redundant mature miRNA sequences, which are associated with PCa, 
which were used as the query dataset and db2 contained all mature miRNAs, 
which were used as the reference dataset. The input was in FASTA format 
datasets (db1, db2) and the output was two files: (i) a FASTA file of sequences in 
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db2 that is dissimilar to db1 and (ii) a text file that lists similar sequences between 
db1 and db2. The text file showed the similarity in clusters generated and 
percentage of similarity between sequences. This was done by running the 
following command line: 
Cd-hit-est-2d –I resultprostatemiRNA.fa -I 2 resultallmiRNA.fa - O similar – c 
0.88 –n 7…………………………………………………………………….... ...(4)  
Where - I is  Db1 which  includes the validated PCa miRNAs, - I 2 is Db2 which 
include all miRNAs, -O is the output, -c sequence identity threshold and –n 7 
word-length.  
2.7 Results 
 2.7.1 Data extraction from Exiqon 
Exiqon is one of the databases that provide information regarding experimentally 
validated miRNAs as well as their involvement in diseases such as cancer. In this 
study, Exiqon was used to collect all miRNA that are currently linked to PCa. 
There is a variety of the databases that provide this type of information. The 
advantage of using Exiqon is that provides information only for the mature 
miRNAs. Consequently, 156 mature miRNAs linked to PCa were collected from 
the Exiqon database as shown in table A.1 Appendix A.  
2.7.2 Sequence extraction using MiRBase 
All miRNA sequences were downloaded from miRBase. Two lists of miRNA 
sequences were generated; first, a list of miRNAs involved in PCa to compare to 
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the list generated by Exiqon, and secondly, a list of 2588 unique mature miRNA 
sequences as shown in table 2.1. 
 
Table 2. 1: Number of sequences extracted from Exiqon and miRBase 
List of miRNAs linked to PCa All mature miRNA deposit in miRBase  
156 sequences  2588 sequences 
2.7.2 Duplication removal 
Duplications were removed using CD-HIT as described in section 2.6.1.3. The 
aim of removing duplications was to avoid repetition of sequences in the same file 
which will affect the result of the similarity search by generating redundancy in 
the results file. After removing duplications two files were generated, (1) a query 
dataset which included 150 miRNAs involved in PCa and (2) a reference dataset 
including 2477 miRNAs as shown in table 2.2.  
Table 2.2: The number of unique miRNA sequence before and after removal of 
duplicates using the CD-HIT program 
Database  miRNAs related to PCa from 
Exiqon 
All miRNAs from miRBase 
before 
removing 
duplication  
After 
removing 
duplication 
before 
removing 
duplication 
After 
removing 
duplication 
Number of 
miRNAs 
156 150 2588 2477 
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2.7.3 Identification of potential novel miRNAs for Prostate Cancer 
2.7.3.1 BLAST for similarity searches 
Sequence similarity is an important aspect in sequence alignments. In molecular 
biology proteins and DNA can be similar with respect to their function(s), their 
structure or their primary sequence of amino or nucleic acids (Ewens and Grant, 
2005). BLAST is widely used for similarity searches of homology among 
different sequences, to evaluate the function of a sequence based on its similarity 
to a sequence of known function, homologous sequences have similar structures, 
frequently they have a similar function as well (Dalal and Atri, 2014).  
The result obtained from BLAST was based on the parameters or settings in the 
command line as described in section 2.6.2.1. The results were displayed as a text 
file with the information of similarity such as (a) mismatching, (b) the start and 
end point of similarity in the length of the sequence, and (c) the percentage of 
similarity indicated. After scanning, the number of sequence similarity between 
the query dataset and reference dataset, there were 258 similar sequences which 
included the 150 PCa miRNAs in both files. The number of PCa implicated 
miRNAs was further removed from the 258 similar sequences leaving a 108 
sequences.  
2.7.3.2 CD-HIT 
The clustering of miRNAs has been proposed for relating the function of 
miRNAs, since miRNAs in gene clusters or families may have functional 
relationships via regulating or co-ordinately regulating biological processes (Guo 
et al., 2014). Studies showed the first evidence of a cluster of miRNAs that could 
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regulate functionally related proteins in cancer (Dews et al., 2006; Xu and Wong, 
2008). 
MiRNA clusters in this study obtained from CD-HIT were 12 clusters including 
16 miRNAs. The clusters were created based on the calculation of their sequence 
similarity with a specific threshold. Only two clusters showed reverse 
complementary with minus sight next to percentage of similarity indicated which 
leaves only 14 unique miRNAs. 
The common results from BLAST and CD-HIT programs showed that 16 
miRNAs had 90 % similarity and above and were considered as potential PCa 
miRNAs for the diagnostic and prognostic purposes, since their similarity was 
with miRNAs linked to PCa and carried forward for further analysis. 
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Table 2. 3: The numbers of miRNA clusters with their percentage of similarity as 
calculated by the CD-HIT and BLAST programs. (The highlighted entry indicates 
the PCa linked miRNA and the entry designated by the alphanumeric letters A, B 
and C its homologous sequence). 
No.  MicroRNAs clusters Percentage of similarity 
1.  23nt,>hsa-miR-1 
23nt,>hsa-miR-1A 
 
at +/95.65% 
2.  23nt,>hsa-miR-2 
23nt,>hsa-miR-2A 
 
at +/95.65% 
3.  23nt,>hsa-miR-3 
23nt,>hsa-miR-3A 
 
at +/91.30% 
4.  23nt,>hsa-miR-4 
23nt,>hsa-miR-4A 
 
at +/91.30% 
5.  23nt,>hsa-miR-5 
23nt,>hsa-miR-5A 
 
at +/91.30% 
6.  22nt,>hsa-let-6 
22nt,>hsa-let-6A 
22nt,>hsa-let-6B 
 
at +/90.91% 
at +/90.91% 
7.  22nt,>hsa-miR-7 
22nt,>hsa-miR-7A 
 
at -/95.45% 
8.  22nt,>hsa-miR-8 
22nt,>hsa-miR-8A 
 
at +/95.45% 
9.  22nt,>hsa-miR-9 
22nt,>hsa-miR-9A 
21nt,>hsa-miR-9B 
 
at +/90.91% 
at +/90.48% 
10.  22nt,>hsa-miR-10 
22nt,>hsa-miR-10A 
18nt,>hsa-miR-10B 
22nt,>hsa-miR-10C 
 
at +/90.91% 
at +/94.44% 
at +/90.91% 
11.  22nt,>hsa-miR-11 
21nt,>hsa-miR-11A 
 
at +/90.48% 
12.  22nt,>hsa-miR-12 
22nt,>hsa-miR-12A 
 
at -/95.45% 
 
2.8 Text mining 
Text mining was performed using different publicly available databases such as 
PhenomiR, Mircancer, and PubMed. PhenomiR is a database providing 
information about the regulation and expression of miRNA in different diseases, 
by using the name of a miRNAs or disease type in the query option. All the 
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potentially novel miRNAs were used as keywords to search if they were related to 
PCa. Six out of the 14 miRNAs were associated with PCa whether down or up-
regulated and were excluded from the candidate miRNA list. Mircancer provides 
information about miRNAs and their association with a variety of cancers. 
MirCancer was used to confirm the implication of the candidate miRNAs in PCa, 
by using the miRNA name as input in the query option. Only three miRNAs were 
associated with PCa with reference articles provided. PubMed was used to access 
all the available articles to confirm the involvement of the miRNAs. 
From the candidate list, 5 putative miRNAs was shorted listed that showed no 
experimental link to PCa (see table 2.4). These miRNAs were carried forward for 
further analysis in the subsequent chapter to confirm their use in diagnostics and 
prognostics of PCa.  
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Table 2. 4: List of experimentally validated miRNAs and candidate miRNAs 
based on text mining 
 Candidate 
MiRNA 
PhenomiR MiRcancer Pubmed article 
ID 
1.  Hsa-miR-1A Linked to PCa Not linked to 
PCa 
17616669 
2.  Hsa-miR-2A Linked to PCa Linked to PCa 25065599 
3.  Hsa-miR-3A Not linked to 
PCa 
Not linked to 
PCa 
Candidate 
4.  Hsa-miR-4A Not Appear Linked 26813459 
5.  Hsa-let-6A Linked to PCa Not Appear 17616669 
6.  Hsa-let-6B Linked to PCa Not Appear 16192569 
7.  Hsa-miR-7A Linked to PCa Not Appear 16192569 
8.  Hsa-miR-8A Linked to PCa Not Appear 16192569 
9.  Hsa-miR-9A Not appear  Not appear  candidate 
10.  Hsa-miR-10A Not linked Not linked candidate 
11.  Hsa-miR-10B Not linked Not linked 20473869 
12.  Hsa-miR-11A Not linked Not linked candidate 
13.  Hsa-miR-11B Not linked Not linked candidate 
14.  Hsa-miR-12A Linked to PCa Linked to PCa 16192569 
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2.9 Discussion 
It has been shown that miRNAs are involved in carcinogenesis through the 
regulation of gene expression (Cinpolat et al., 2017). The recognition of 
differentially expressed miRNAs in a tumour, as well as normal tissues, may help 
to establish the pathogenic role of miRNAs in cancer (Di Lisio et al., 2012). A 
previous study has demonstrated the presence of miRNA differential expression 
profiles in cancerous tissues as compared to normal tissues (Schetter et al., 2008). 
These cancer types include lung cancer, leukemia, brain cancer, prostate, and 
breast cancer (De Bock et al., 2010). The value of miRNA profiles in tumour 
diagnostics is well-established. For example, 16 miRNAs have been shown to be 
strongly down-regulated in breast cancer (Aqeilan, Calin and Croce, 2010). 
In this study, potentially novel miRNA biomarkers for PCa were identified using 
similarity search methods between PCa experimentally validated miRNAs and all 
miRNAs deposited in the miRBase database. 
A list of the experimentally validated miRNAs was generated from the Exiqon 
database containing 156 miRNAs which by given name of the miRNA and the 
reference articles showed their involvement in PCa. All the mature miRNA 
sequences were collected using the miRBase database by using the name of 
individual miRNAs as a keyword. After the search, the mature and precursor 
sequence was obtained, and only the mature miRNAs were considered for the 
study. The reference dataset was collected from miRBase and included 2588 
miRNAs sequences all deposited for Homo sapiens. This dataset was used as a 
reference dataset to scan the experimentally validated dataset against to identify 
potentially new miRNAs for PCa. Overlapping (redundancy) data could lead to an 
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undesirable result file. Therefore, it was essential to remove duplications from 
both datasets (the reference as well as query dataset). The CD-HIT program was 
used to remove duplication from the datasets with the resulting file for the PCa 
experimentally validated miRNAs containing 150 unique miRNA sequences and 
the reference file containing 2477 unique miRNA sequences. 
Local BLAST was used to increase the robustness of the search for similarity. 
Two steps in BLAST based searches were employed. First, a database was built 
by using all the mature miRNAs which included 2477 sequences. Second, the PCa 
experimentally validated miRNAs was scanned against this database with the 
results file containing 258 miRNAs indicating the percentage of similarity 
between the sequences. This file also included the 150 miRNAs that showed a 
link to PCa with the resulting file containing 108 miRNAs after removal of the 
150 miRNAs. 
CD-HIT was used to find the similarity between the miRNAs from the query and 
reference datasets (db1 and db2). The results obtained included 12 clusters and 
contained 16 miRNAs. The cluster contains the miRNAs that are linked to PCa as 
well as its sequence homolog not linked to PCa with the understanding that these 
two miRNAs are clustered based on their sequence similarity and can potentially 
have a similar function(s) and/or participate in similar bioprocesses.  
To minimize the amount of results in this study, two criteria were used: (i) 
common results from both programs, (ii) only miRNAs with equal to and more 
than 90 % similarity were considered as potential miRNAs for diagnostic and 
prognostic purposes of PCa. 
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In conclusion, 16 miRNAs were clustered from CD-HIT as well as BLAST. Two 
miRNAs were excluded from this study as they were reverse complement 
sequences and 14 miRNAs were text mined in three different databases to ensure 
they are not linked to PCa. The five miRNAs that showed no linked to PCa, 
however, sharing sequence similarity to miRNAs implicated in PCa were selected 
for further analysis as explained in the subsequent chapters. 
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Chapter 3 
Identification of target genes in prostate cancer for candidate miRNAs using 
an in silico approach 
 
3.1 Introduction 
Prostate cancer is a major health problem worldwide, with one of the main causes 
being epigenetic (Sharma, Kelly and Jones, 2009). Epigenetic mechanisms appear 
to be responsible for a significant proportion of the alterations in cancer (Riley 
and Anderson, 2011). A gene is the basic functional unit of DNA which expresses 
to form the primary structure of proteins. In neoplasia, there is a profound 
alteration in the patterns of DNA methylation as well as in the structural 
composition of chromatin.  In studies based on the organisational behaviour of 
chromatin involved in the modulation of gene transcription, the significance of the 
epigenetic mechanisms present in the initiation and progression of human cancers 
has been further highlighted (Jones and Baylin, 2002; Wille, 2017). These 
epigenetic changes include aberrant promoter hypermethylation along with 
inappropriate gene silencing, which virtually influences each step in tumour 
progression (Jones and Baylin, 2002). 
The current literature available on tumour-profiling studies facilitates the 
comprehensive comparison of the expression patterns of genes associated with the 
cell-cycle of different tumour types. These studies have shown that the 
„proliferation signature‟ of the genes whose expression directly correlate with 
cell-cycle status, tumour mitotic grade as well as their doubling times, were 
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observed to be the most conserved patterns of expression in cancerous cells 
(Whitfield et al., 2006). However, the exact number of genes comprising this 
„proliferation signature‟ often varies, but usually, these are the genes that are 
involved in the vital process of cell proliferation. The understanding of this 
„proliferation signature‟ can be used to improve the understanding of the cell 
cycle involvement in cancer pathogenesis and can be utilised as a biomarker for 
cancer diagnosis as well as prognosis (Whitfield et al., 2006). 
In addition, genes are regulated by miRNAs which are involved in cellular 
processes such as differentiation, apoptosis and morphogenesis. miRNAs perform 
regulation in negative reciprocal feedback loops, in association with protein co-
factors that govern signal transduction triggered cell fate decisions (Carthew, 
2006). miRNAs are small, non-coding, endogenous RNA molecules that play an 
important role in a variety of normal and diseased biological processes through 
post-transcriptional regulation. They can bind to target mRNA transcripts of 
protein-coding genes and negatively control their translation or cause mRNA 
degradation (Zheng et al., 2013). 
In recent decades, the sophistication of bioinformatics algorithms increased the 
accuracy regarding the identification of the genes regulated by miRNAs 
(ReyesHerrera and Ficarra, 2012). The in silico methods can efficiently identify 
the functionalities of genes which are significant in the processes of diagnosis and 
the prognosis of therapies against a diverse number of cancers (ReyesHerrera and 
Ficarra, 2012). A variety of bioinformatics databases such as MirDIP, TiGER, 
DAVID, and STRING were designed for the prediction of miRNA target genes, 
their functions and interactions, as well as their expression across a variety of 
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tissues, be it normal or diseased (Huang et al., 2007; Liu et al., 2008a; Shirdel et 
al., 2011). In this chapter, an array of online databases was used to identify and 
functionally annotate the target genes for the five miRNAs as potential 
biomarkers for PCa, identified in Chapter 2. 
3.2 Use of available databases for target gene identification 
Several online databases, which facilitate data retrieving and analysis, were used 
to identify the miRNA target genes as well as their involvement in PCa. The 
details on each database are explained in the subsequent sections. 
3.2.1 Use of mirDIP microRNAs Data Integration Portal  
MirDIP (http://ophid.utoronto.ca/mirDIP/) is a publically available repository, 
which integrates the latest information regarding miRNA target predictions, 
collected from 11 distinct source prediction databases (Stark et al., 2003; Betel et 
al., 2008). MirDIP combines the expression data from three miRNA databases, 
namely, MiRanda, TargetScan and picTar, providing a more efficient way than 
other available methods for users to control the prediction data (Nam et al., 2008). 
The flexibility in target gene prediction allows the user to choose the appropriate 
combination of the 11 databases suitable to their query. Furthermore, mirDIP also 
integrates NAViGaTOR (Brown et al., 2009). Which offers scalable network 
analysis as well as a visualisation system for viewing the novel miRNA: target 
predictions (Shirdel et al., 2011). MirDIP predictions in this study were based on 
eleven criteria as listed below. 
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(1) The search is primarily based on seed sequence matches that allows base-pair 
mismatches as well as G: U wobbles, which is significant for miRNA binding. 
This prediction protocol identifies a high degree of complementarity between the 
miRNA‟s 5′ end as well as the 3′ end of the mRNA target sequence, with specific 
attention to the seed region which is 2–8 bases long from the 5′ end of the miRNA 
(Wuchty et al., 1999). 
(2) Other criteria included conservation of the binding sequence of miRNA to the 
mRNA target, with a more reliable prediction being made if there is a high level 
of conservation to the target site. This step was considered as the „Filtering Step‟ 
since the bias in the results will be reduced by using the predictions with as well 
as without conservation measures (Miranda et al., 2006; Kertesz et al., 2007; 
Shirdel et al., 2011). 
(3) The Free Energy (ΔG) of miRNA: mRNA duplex formation was also 
considered and calculated using the Vienna Folding package which estimates the 
energy essential for the formation of the miRNA: mRNA duplex from an entirely 
dissociated state (McCaskill, 1990). 
(4) Another energy-based parameter, i.e, site accessibility is measured in ΔΔG and 
compares the energy required for the unfolding of a folded 3′ UTR to allow the 
accessibility of a miRNA to its target site as well as refolding into the miRNA: 
mRNA duplex (Shirdel et al., 2011). 
(5) In order to evaluate the dose-dependent effects of microRNAs on target gene 
expression, the contribution of its multiple binding sites in the 3′ UTR of a 
particular gene was also considered. Co-operativity with these binding sites 
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results in synergistic gene repression (Doench and Sharp, 2004). Previous studies 
have shown that the distance of novel inter-binding sites is present between 8–40 
bp (Sætrom et al., 2007). 
(6) Local ALU content is the segments of duplicate DNA interspersed within the 
human genome, although it is generated by retro-transposons it is named after the 
enzyme Alu1, which is responsible for its cleavage (Batzer and Deininger, 2002). 
It is used in TargetScan to measure context score and enrichment of A or U base-
pairs in the 30 nucleotides up or downstream of the microRNA binding site in the 
3′ UTR. Furthermore, it tends to be favourably associated with repression of the 
target gene‟s expression (Lewis, Burge and Bartel, 2005; Shirdel et al., 2011). 
(7) Local mRNA sequence. The consideration of sequence nearby the microRNA 
binding site on the 3′ UTR is sometimes considered. Algorithms may examine 
sequence content for specific nucleotides or examine local sequence effect on site 
accessibility (Lewis, Burge and Bartel, 2005; Grimson et al., 2007). 
(8) Ribosomal shadow is also considered in miRNA target prediction and is taken 
into consideration by the TargetScan database. It has been hypothesised that 
repression by miRNAs is caused by a ribosomal shadow effect  (Grimson et al., 
2007). 
(9) The use of miRanda, the first miRNA alignment algorithm, which is similar to 
the Smith-Waterman algorithm for sequence alignment and uses the same rules of 
thumb previously established for sequence alignment (Enright et al., 2003; John et 
al., 2004). 
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(10) Positional effect. Positional effect rewards miRNA target sites that fall within 
the first or final quartile of the 3′ UTR after the stop codon (+15 base-pairs), near 
to the poly (AAAA) tail. This effect is more noticeable in long UTRs (Grimson et 
al., 2007). 
(11) 3′ Pairing. Aside from strong seed region pairing, miRanda also requires 
nucleotide binding between the microRNA and the target mRNA between bases 
12–17 of the 3′ end of the microRNA for miRNA target prediction (Grimson et 
al., 2007). 
3.2.2 Tissue-specific Gene Expression and Regulation 
TiGER (Tissue-specific Gene Expression and Regulation) obtainable at 
http://bioinfo.wilmer.jhu.edu/tiger/ is a database that contains tissue-specific gene 
expression profiles or expressed sequence tag (EST) data, cis-regulatory module 
(CRM) data, and tissue-specific transcription factor interaction data in 30 human 
tissues for each gene contained within the database (Liu et al., 2008b). At present, 
the database contains expression profiles for 19,526 UniGene genes, 
combinatorial regulations for 7,341 transcription factor pairs and 6,232 putative 
CRMs for 2,130 RefSeq genes (Liu et al., 2008). 
The gene expression pattern for each UniGene is calculated based on the NCBI 
EST database. TiGER has identified and catalogued 7261 tissue-specific genes for 
30 human tissues based on their expression enrichment and statistical 
significance. Thus, on average, each tissue expresses approximately 290 tissue-
specific genes (Yu et al., 2007). 
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In addition to EST data, TiGER also identifies transcription factors (TFs) based 
on patterns of co-occurrence of pairs of DNA binding sites (Yu et al., 2007). 
TiGER predicts 9060 tissue-specific TF interactions, around 300 for each tissue 
(Yu et al., 2006). The database uses known interactions as positive controls 
attributable to the scarcity of tissue-specific interactions to evaluate these results. 
Cis-regulatory modules (CRMs) are a stretch of DNA usually about 100-1000 
base pairs in length where several transcription factors can bind (Istrail and 
Davidson, 2005). They are the central cis-elements that control gene expression 
(Istrail and Davidson, 2005). TiGER calculates the interaction strength between 
two transcription factor (TF) binding sites and then derives an empirical „potential 
energy‟ for each TF-binding site. This results in energy profiles for the promoter 
sequences of tissue-specific genes. An energy level less than -1 indicates the 
existence of a TF module (Liu et al., 2008b). 
This development of computational methods for tissue-specific combinational 
gene regulation, based on transcription factor binding sites, CRMs and ESTs 
enables the platform to perform a large-scale analysis of tissue-specific gene 
regulation in human tissues (Liu et al., 2008). 
3.2.3 Intersection analysis by Venn diagrams 
Venn diagrams tool accessible at 
http://bioinformatics.psb.ugent.be/webtools/Venn/ is used to calculate the 
intersection between lists of elements or data. The tool generates a textual output 
indicating which elements are at each intersection or are unique to a certain list. 
The user has a choice between symmetric and non-symmetric Venn diagrams. 
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Currently, the user can calculate the intersections of a maximum of 30 lists (Draw 
Venn diagram, n.d). 
3.2.4 Functional characterisation of genes via DAVID  
DAVID (Database for Annotation, Visualization and Integrated Discovery), is a 
database that has several features and is publicly available at 
(https://david.ncifcrf.gov/). DAVID is a high-throughput annotation tool that 
systematically maps a large number of interesting genes to a list of associated 
Gene Ontology terms and then statistically highlights genes that are over-enriched 
for those terms (Ashburner et al., 2000). This increases the possibility that the 
researcher will identify the involvement of the gene of interest in different disease 
states and another biological process (Huang et al., 2007). The annotation tool in 
DAVID provides several gene annotation options including; LocusLink, Unigene, 
GenBank, Gene Symbol, RefSeq Gene Name, OMIM, Affymetrix description, 
Summary and Gene Ontology. Each of these tools can be used for various reasons 
or functions, In this study, the Gene disease associated tool will be of interest for 
the identification of the genes that are involved in our disease of interest (Huang 
et al., 2007). 
3.2.5 Gene/protein interaction analysis via STRING 
The STRING (https://string-db.org/) database (Search Tool for the Retrieval of 
Interacting Genes/Proteins) aims to provide comprehensive, yet a quality 
controlled collection of protein-protein associations for several organisms. The 
associations are derived from high throughput experimental data, from the mining 
of databases and literature, and from predictions based on genomic context 
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analysis with version 10.0 covering 2031 organisms (Szklarczyk et al., 2015). The 
basic interaction unit in STRING is the functional association, i.e, a specific and 
productive functional association between two proteins, likely contributing to a 
common biological purpose. Interactions are derived from multiple sources, (i) 
known experimental interactions are imported from primary databases; (ii) 
automated text-mining is applied to uncover statistical and/or semantic links 
between proteins, based on Medline abstracts and a large collection of full-text 
articles; (iii) pathway knowledge is parsed from manually curated databases; and 
(iv) interactions are predicted de novo by a number of algorithms using genomic 
information (Szklarczyk et al., 2015). 
3.2.6 KEGG pathway analysis 
KEGG (Kyoto Encyclopedia of Genes and Genomes) is a knowledge base for 
systematic analysis of gene functions, linking genomic information with higher 
order functional information access at (https://david.ncifcrf.gov/). The genomic 
information is stored in the GENES database, which is a collection of gene 
catalogues for all the complete sequenced genomes and some partial genomes 
with up-to-date annotation of gene functions. The higher order functional 
information is stored in the PATHWAY database, which contains graphical 
representations of cellular processes, such as metabolism, membrane transport, 
signal transduction and cell cycle. The PATHWAY database is supplemented by a 
set of ortholog group tables for information about conserved sub-pathways 
(pathway motifs), which are often encoded by positionally coupled genes on the 
chromosome and which are especially useful in predicting gene functions. The 
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third database in KEGG is LIGAND for the information about chemical 
compounds, enzyme molecules and enzymatic reactions. KEGG provides Java 
graphics tools for browsing genome maps, comparing two genome maps and 
manipulating expression maps as well as computational tools for sequence 
comparison, graph comparison and path computation (Kanehisa and Goto, 2000). 
3.3 Aim and objectives  
The aim of this chapter is to identify the gene targets of the five miRNAs 
previously identified and to link these genes to PCa. Thus, linking their regulating 
miRNAs to PCa indirectly since these short-listed miRNAs showed no link to PCa 
(see Chapter 2). 
I. To identify the target gene for the candidate miRNAs using the mirDIP 
database; 
II. Extraction of all genes expressed in prostate tissue based on expression 
sequence tag (EST) data using the TiGER database;  
III. Functional annotation of the target genes to PCa using the DAVID 
database; 
IV. Perform Pathway analysis of the target genes using KEGG; and   
V. Gene interaction network analysis of the target genes via STRING. 
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3.4 Methodology 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Outline of the in silico methodology for prioritising of the miRNA 
target genes 
List of genes common to mirDIP and TiGER 
DAVID database to annotate the common genes from the previous 
step to PCa 
Gene pathway analysis using 
KEGG in the DAVID database 
Gene interaction analysis 
using the STRING database 
Venn diagram for identification of intersecting genes generated from 
mirDIP and TiGER 
Identification of the target 
genes for the 5 miRNAs using 
mirDIP 
List of all genes expressed in 
prostate tissue extracted from 
TIGER database 
Final list of genes with clear links to PCa 
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3.4.1 Use of mirDIP microRNAs Data Integration Portal 
The mirDIP database was accessed at (http://ophid.utoronto.ca/mirDIP/) on 
15/03/2017, for the identification of target genes for each of the miRNA clusters. 
The previously identified four clusters containing the five miRNAs were 
submitted separately to the mirDIP database to identify common target genes for 
each cluster. The database was used with the default settings. 
3.4.2 TiGER to extract prostate tissue expressed genes 
TiGER was used to extract all the genes that are expressed in prostate tissue by 
selecting “prostate tissue” as a keyword in the query section. TIGER produce 
three subsets of data based on three principles, (i) Expressed Sequence Tags 
(ESTs); (ii) Cis-Regulatory Modules (CRMs); and (iii) Combinatorial Gene 
Regulation. The expressed sequence tags module was selected for this study. A 
list of genes expressed in prostate tissue was compiled and saved for further 
analysis. 
3.4.3 Intersection analysis by Venn diagrams 
Venn diagrams were used to calculate the intersection between the lists of genes 
obtained in sections 3.4.1 and 3.4.2 by generating a textual output indicating 
which genes were in each intersection or were unique to a certain list. This online 
tool was used to see the intersection between the four lists of target genes 
generated by mirDIP (representing the four miRNA clusters) with the list of the 
genes generated by TiGER (prostate specific genes). All the intersections were 
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submitted at the same time, and the results are shown in figure 3.2. The 
intersecting genes from each cluster were saved in a separate file.  
3.4.4 Involvement of genes in prostate cancer using the DAVID database 
DAVID database was accessed at https://david.ncifcrf.gov/ to functionally 
annotate the miRNA target genes and was used with the following steps, (i) In 
“Enter Gene List” option, four lists of genes (list of genes from each miRNA 
cluster) were pasted individually in the query box; (ii) Under the “select 
identifier” option, official gene symbol was selected; (iii) “List of genes” was 
selected followed by selection of the “submit” option. On the next page several 
options are available, the disease option were selected after which 
GRD_DIESEASE was selected. The chart output places the genes in various 
cancer processes with special emphasis on PCa for this study. The analysis 
generated lists of genes involved in PCa and was saved in an Excel file (see table 
3.3). 
 3.5 KEGG Pathway analysis of the genes in prostate cancer 
KEGG pathway analyses were carried out in DAVID, Bioinformatics Resources 
at http://david.abcc.ncifcrf.gov (Huang, Lempicki and Sherman, 2009). The List 
of genes previously shortlisted was submitted to the DAVID database for pathway 
analysis using the KEGG functionality within DAVID. Results were given as 
pathway graphs for the genes that are involved in known PCa processes as shown 
in figure 3.3. 
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3.6 Analysis of Gene/protein interaction network 
Gene IDs for a list of genes identified by DAVID implicated in PCa were used as 
input for the generation of gene networks using the STRING database Version 10 
(Meiring, 2003; Franceschini et al., 2013). First, the genes were used as input to 
generate an expression network among each other. To produce this expression 
network, parameters were chosen as follows, (i) a confidence level of 0.7 and (ii) 
a network depth of 4. Second, an extended network was produced to determine 
which of the genes showed links to known genes involved in cancer and 
specifically in PCa using (i) a confidence level of 0.7 and (ii) a network depth of 
5. The results are given as a „stick/line and ball‟ graphic with the „balls‟ 
(proteins/genes) connected by different colour lines with each colour indicating 
the type of evidence for the connection between each protein/gene.  
3.7 Results 
3.7.1 MirDIP miRNAs target gene prediction 
The four miRNA clusters were used as input in mirDIP database as explained in 
section 3.2. Four lists of miRNAs target genes were generated for these miRNA 
clusters which included five miRNAs. The common target genes resulting from 
each cluster were filtered. The function(s) of gene targets is regulated by more 
than one miRNA indicating that these genes are functionally similar and share 
common features closely related to various cancers such as apoptosis, cell 
proliferation, transcription regulation and diverse cancer-related pathways (Liu et 
al., 2016). From the result, a total of 56 339 target genes were identified for the 
five miRNAs sharing 42 731 genes amongst themselves (see table 3.1)   
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Table 3.1: The number of target genes in each miRNA cluster and common target 
genes produced by mirDIP 
Cluster  
MicroRNA in 
each cluster  
Number of 
target genes 
Number of 
common target 
genes  
Cluster 1 
Hsa-miR-1 
Hsa-miR-1A 
13 575 12 952 
Cluster 2 
Hsa-miR-2 
Hsa-miR-2A 
11 114 10 555 
Cluster 3 
Hsa-miR-3 
Hsa-miR-3A 
15 864 9 626 
Cluster 4 
Hsa-miR-4 
Hsa-miR-4A 
Hsa-miR-4B 
15 786 9 598 
Total number of target genes  56 339 42 731 
3.7.2 TiGER database  
A list of genes expressed in prostate tissue was collected from the TiGER 
database by using “prostate tissue” as a keyword. Based on the EST database a 
number of genes (201) was collected as displayed in table 3.2, and the data was 
saved in an excel file. Each of the genes collected from TiGER showed a 
relatively high expression in prostate tissue. After removal of duplications, 148 
unique genes remained. 
Table 3.2: Shows the number of genes expressed in prostate tissue as determined 
by TiGER 
Keyword  List of genes from 
TiGER 
List of genes after 
removing duplications   
Prostate tissue  201 148 
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3.7.3 Venn diagram of intersectiing genes  
Venn diagrams were generated by using the online tool representing the 
intersection between the genes expressed in prostate tissue and the target genes. 
The intersecting genes for cluster one numbered 66 genes, for cluster two 47 
genes, for cluster three 46 genes, and for cluster four 53 genes as shown in figure 
3.1. 
 
Figure 3.2: Venn diagrams for representing the number of intersecting genes for 
the four miRNA clusters. List A: target genes generated by mirDIP and List B: 
genes expressed in prostate tissue generated by TiGER.  
3.7.4 DAVID database result involving genes in prostate cancer  
As mentioned in section 3.5.4, the DAVID database was used to confirm the link 
of the target genes in PCa. The list of intersecting genes for each cluster was 
submitted to DAVID with the number of genes functionally annotated to PCa 
indicated in table 3.3 several of the genes showed enrichment for a functional 
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annotation to PCa across the clusters with 12 genes being unique to the four 
clusters. 
Table 3.3: Number of genes from intersection submitted to DAVID 
List of genes from  
intersection 
Number of intersecting 
genes 
List of genes annotated 
to PCa using the 
DAVID database 
Cluster 1 66 10 
Cluster 2 47 9 
Cluster 3 53 10 
Cluster 4 46 8 
List of unique genes  12 
 
Table 3.4: The list of gene names for each cluster annotated to PCa 
Genes from 
Cluster 1 
Genes from 
cluster 2 
Genes from 
cluster 3 
Genes from 
cluster  
4 
NKX3-1 NKX3-1 NKX3-1 NKX3-1 
AMACR AMACR AMACR AMACR 
AR AR AR AR 
CYP24A1 IGF1 CYP24A1 CYP24A1 
IGF1 KLK2 IGF1 IGF1 
KLK4 KLK3 KLK2 MYH11 
MYH11 KLK4 MYH11 PTGS2 
PTGS2 PTGS2 PTGS2 SRD5A2 
SRD5A2 TMPRSS2 SRD5A2  
TMPRSS2  TMPRSS2  
3.7.5 KEGG pathway analysis through DAVID database  
The list of genes that are involved in PCa as determined by DAVID for all 
clusters was combined and include the following genes, AMACR, AR, CYP24A1, 
IGF1, KLK2, KLK3, KLK4, MYH11, NKX3-1, PTGS2, SRD5A2 and TMPRSS2. 
To determine if any of these genes were involved in PCa pathways all of the 
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genes were submitted to the KEGG functionality within the DAVID database. 
Five out of the twelve genes were implicated in known PCa pathways using 
KEGG, viz NKX3-1 AR, IGF1, KLK3, and SRD5A2 with KEGG ID 05215 as 
shown in figure 3.3  
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Figure 3.3: Shows the implication of 5 genes (AR, SRD5A2, IGF1, KLK3, and 
NKX3-1) out of 12 genes in PCa pathways with the genes highlighted in red. Link 
for the graph can be obtained at 
(https://david.ncifcrf.gov/kegg.jsp?path=hsa05215$Prostate%20cancer&termId=5
50028904&source=kegg) 
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3.7.6 Gene interaction analysis using STRING database 
The twelve genes were submitted to STRING to generate an interaction network 
amongst themselves as described in section 3.6. The result indicates that there are 
several lines of evidence for the interaction between 5 out of 12 genes as shown in 
figure 3.4. From the graphic result, the interactions between AR and TMPRSS2, 
AR and KLK3, AR and NKX3-1 and KLK2 and AR are supported by several lines 
of evidence which includes experimentally determined, from curated databases 
and text mining. There was no evidence to link KLK4, CYP24A1 and PTGS2 to 
the network. This could be due to the fact that information for these genes was not 
available at the date of analysis SRD5A2 did not show up at all in the network, 
which could also be due to a lack of information on this gene. However, it was 
placed in known PCa pathways using KEGG. 
 
Figure 3.4: Protein Network Visualization generated by STRING. The 
interactions of the 11 miRNA targeted genes clustered together. The genes are 
represented by the nodes and the different line colours represent the types of 
evidence for the interaction. Indicate the evidence and the colours. 
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The second result from STRING for the miRNA targeted genes are depicted in 
figure 3.5. From the results, five additional genes, namely IGFBP3, HSP90AA1, 
IGFBP1, CTNNB1, and NCOA2 showed interaction with the miRNA target genes, 
with the lines of evidence equally convincing as with the generation of the first 
interaction network. 
 
Figure 3.5: Interaction network between the genes and other genes of interest 
using STRING. The genes in the outlined box were associated with target genes 
with their evidence. 
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3.8 Discussion 
Genes play a critical roles in different diseases including cancer and they are 
involved in different cellular processes such as cell proliferation, apoptosis, 
differentiation, migration and maturation, with all these processes being involved 
in the performation of tumours (Thompson, 1995; Chen and Lai, 2009) 
Understanding how genes are expressed and regulated in various tissues under 
various conditions can help clarify the molecular mechanisms of tissue 
development and their functions in cancer (Liu et al., 2008). The changes in gene 
expression can be identified or evaluated by both molecular and in silico gene 
expression analysis for diseased and normal states. Gene expression profiling 
allows for the sub-classification of tumours by providing diagnostic and 
prognostic information of genes that are differentially expressed in tumours as 
well as their regulating miRNAs (Thomas et al., 2013). 
In this chapter, various databases were systemically used to identify the target 
genes for the five miRNAs identified in the previous chapter. Five potentially 
novel miRNAs were identified as diagnostic and prognostic biomarkers for PCa 
using various in silico methods.  
To understand how these miRNAs are associated with PCa, examination of their 
target gene regulation was carried out using in silico approaches. 
The mirDIP database was employed to identify the target genes of the five 
miRNAs. The prediction of these genes was based on the eleven criteria stipulated 
in section 3.2.1. From the miRDIP target gene prediction analysis, a total of 
56,339 target genes were identified for the five miRNAs divided into four 
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clusters. After the removal of duplications, the clusters shared 42 731 genes. The 
number of genes was expected since a single miRNA can regulate the function of 
thousands of genes. This regulation however is determined by certain stimuli, and 
physiological conditions, tissue specificity and various other biological factors. 
The next step was to download all genes expressed in prostate tissue with the 
rationale that if a particular gene is expressed in prostate tissue and it is regulated 
by a miRNA with known links to PCa, the potentially novel PCa miRNAs might 
function in a similar biological process and regulate the expression of known PCa 
associated genes. From the TiGER database, a list of 148 genes was collected by 
using “prostate tissue” as the search keyword. The list from TiGER and the four 
lists from mirDIP were used to performed intersection analysis using Venn 
diagrams. The intersections were drawn online between the miRNA target genes 
from mirDIP for each cluster and the genes expressed in prostate tissue from 
TiGER. The intersecting genes numbered 66 genes for the first cluster, 47 genes 
for the second cluster, 46 genes for the third cluster, and 53 genes for the fourth 
cluster. 
All the genes from each cluster highlighted in the intersection analysis were 
submitted to DAVID. DAVID is a functional annotation database to confirm the 
involvement of these genes in different types of diseases based on the 
experimental result. For this study, PCa was selected as the disease category with 
a few number of intersecting genes from each cluster implicated in PCa as per the 
results of DAVID. 
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From cluster one containing 66 genes, 10 genes were implicated in PCa, cluster 
two 9 out of 47, cluster three 10 out of 46 genes and cluster four 9 out of 53 genes 
were implicated within PCa. These lists of the genes were extracted, combined 
and duplications removed resulting in a list of 12 unique genes as targets for the 
five miRNAs. 
To further support these genes as implicated in PCa, pathway analysis was carried 
out using KEGG within the DAVID database. The list of 12 genes was submitted 
to DAVID database for KEGG pathway analysis with five out of 12 genes 
showing involvement in PCa pathways. AR, TMPRSS2, KLK3, NKX3-1 and KLK2 
were all placed in PCa pathways using KEGG. 
The growth and maintenance of the prostate are reliant on androgen acting 
through the Androgen Receptor (AR). AR is important in the development and 
progression of PCa (Heinlein and Chang, 2004). The AR plays an essential role in 
the expression of male phenotype and alteration of AR function is associated with 
PCa (Tan et al., 2015). The wild-type AR can induce cellular differentiation or 
cellular apoptosis in PCa cells (Fu et al., 2003). Somatic missense AR gene 
mutations have been detected in PCa cell lines (Fu et al., 2003). 
 In a study, it was shown that NKX3.1 is a prostate-specific homeobox gene which 
controls differentiation, epithelial cell growth, and stem cell maintenance (Song et 
al., 2015). Inadequate levels of PTEN and NKX3.1 lead to a reduction in p27 
levels and increase proliferation and decrease apoptosis clearly demonstrating 
their role in tumour formation (Song et al., 2015). 
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The result of a study demonstrated that the SRD5A2 rs9282858 polymorphism 
was remarkably associated with an increased susceptibility to PCa (Fang et al., 
2017). SRD5A2 is primarily expressed within the prostate and testes and plays a 
major role in the prostate function and disease aetiology. Thus, SRD5A2 inhibitors 
such as dutasteride and finasteride have been developed to manage BPH and 
potentially prevent PCa (Sissung et al., 2014). 
TMPRSS2 protein function in prostate carcinogenesis relies on overexpression of 
ETS transcription factors, such as ERG and ETV1, through gene fusion (Yu et al., 
2010).Also another study suggest that fusion of TMPRSS2: ERG may lead to a 
more aggressive PCa phenotype and possibly account in part to higher grade PCa 
(Demichelis et al., 2007). 
KLK3 also known as prostate specific antigens is already being used as a 
diagnostic biomarker for PCa, a member of the fifteen-gene family kallikrein-
related peptidase (KLK), in blood has revolutionized both the detection and 
management of PCa (Hong, 2014). KLKs have more promising use as diagnostic 
and prognostic value because of the essential similarities between PSA and 
other KLKs (Hong, 2014). 
IGF-1 has been shown to stimulate the proliferation of human prostate epithelial 
cells (PEC) in culture, and is necessary for normal growth and development of the 
rat and mouse prostate, the link between high circulating serum IGF-1 levels and 
the risk of developing advanced PCa later has been established in epidemiological 
studies (Roberts, 2004). In a previous study, there is significant evidence of 
associations between total IGF-1R and risk of overall and metastatic recurrence, 
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and between cytoplasmic or internalised IGF-1R and biochemical recurrence, 
following radical radiotherapy but not surgery for PCa (Aleksic et al., 2017). 
STRING database confirmed the interaction between the lists of genes which 
included 12 genes of which only 11 genes showed interaction as shown in figure 
3.4. One gene did not appear in the STRING analysis and there might not be 
enough information published on this gene. Three genes are involved in 
Biological Processes mainly in prostate gland development namely AR, IGF, and 
NKX3-1 (Holzbeierlein et al., 2004) and six genes are involved in the Molecular 
Functions namely KLK2, KLK3, KLK4, TMPRSS2, AR and NKX3-1.  
AR was central in the gene interaction network, with three lines of evidence 
connecting it to its interaction partners namely experimentally determined, from 
curated databases and text mining. The main function of AR is that of a DNA-
binding transcription factor that regulates gene expression. Some of the genes 
were linked only by text mining evidence such as MYH11, which was linked to 
IGF1 and AMACR which was linked to AR.  
Antibodies to AMACR were used in an immunohistochemistry experiment to 
demonstrate the presence of prostate carcinoma since the enzyme is greatly 
overexpressed in this type of a tumour, with this study performed on prostate 
tissue (Evans, 2003). 
One gene did not appear in the STRING database analysis namely SRD5A2. 
However, epidemiological and biochemical findings showed an association 
between PCa and a constitutional (germline) missense substitution in SRD5A2, 
which resulted in the replacement of an alanine residue at codon 49 with threonine 
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(A49T). This substitution is associated with a significantly increased risk of PCa, 
probably through increased metabolic activation of testosterone to 
dihydrotestosterone (Makridakis et al., 1999). The result of interaction confirmed 
that these genes namely AR, KLK3, KLK2, IGF1 and NKX3-1 are highly involved 
in prostate gland development and any change in these genes might result in the 
performance of a tumour. 
Secondly, the extended interaction analysis using STRING five additional genes 
namely IGFBP, HSP90AA1, IGFBP3, CTNNB1, and NCOA2 showed interactions 
with the miRNA target genes as shown in figure 3.5. 
The central genes in the first interaction network as shown in figure 3.4 AR were 
linked to two more genes namely NCOA2, HSP90AA and IGFBP-3 showing 
interaction with IGF1 and KLK3 by three lines of evidence. IGFBP-3 protein 
levels have been reported to decrease during the progression of PCa from benign 
to metastatic disease. Although production of the protein does not cease 
completely, IGFBP-3 is still made at a lower level by PCa cells and secretes into 
the surrounding environment. However, instead of the full length functional 
protein, IGFBP-3 is found to be cleaved. This decreases the affinity of IGF 
binding to IGFBP-3, making the growth factors more likely to bind the IGF1 
Receptor and thus promoting cell survival (Brahmkhatri, Prasanna and Atreya, 
2015). In a previous study, it was found that PCa patient samples revealed a 
strong correlation between NCoA2-mediated signalling, PCa recurrence and 
disease progression (Qin et al., 2014). Deprivation of androgen induces NCoA2,  
which mediates activation of PI3K signalling and promotes PCa metastasis and 
castration-resistant PCa development (Qin et al., 2014). IGFBP-3 is anti-
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angiogenic and a pro-apoptotic protein in PCa. In epidemiologic studies, it was 
suggested that low IGFBP-3 is associated with greater risk of aggressive, 
metastatic PCa (Mehta et al., 2011). 
In conclusion, using a combination of in silico tools, target genes for the five 
miRNAs were identified. Through functional annotation, pathway analysis a list 
of miRNA target genes was created resulting into 12 genes regulated by five 
miRNAs. 
In the subsequent chapters, both the genes and their regulating miRNAs will be 
further examined as putative biomarkers for PCa management using various in 
silico tools. 
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Chapter 4 
Use of the identified miRNAs and their target genes as potential prognostic 
biomarkers for PCa using an in silico approaches 
 
4.1 Introduction  
Prognostic biomarkers provides information on the likely course of cancer in an 
untreated individual that are objectively measurable (Italiano, 2011). Recently, the 
discovery of miRNA has provided new insights into cancer research, revealing the 
role of miRNAs in various biological processes, and evidence shows that their 
deregulation in many cancers has prognostic and predictive significant value (Pal 
et al., 2015). For cancer prognosis, miRNA can be complementary to other 
genomic and proteomic biomarkers (Lan et al., 2015). The possible applications 
of miRNAs not only in molecular diagnostics but also in molecular prognostics, 
particularly in cancer, are provided by the discovery of the role of miRNA in 
numerous pathological processes.  
 
MiRNAs serve as diagnostic, prognostic and predictive biomarkers for different 
types of cancer by investigating the expression of miRNAs at a different stage of 
cancer  (Kosaka, Iguchi and Ochiya, 2010).  
4.2 MiRNA as a prognostic biomarker  
A prognostic biomarker aids in monitoring the progression of a disease and 
provides information on its likely outcome in an untreated individual (Italiano, 
2011). Cancer genomics contributed to prognostic biomarker discovery, which 
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may include molecular signatures such as polymorphisms, genes, mutations, 
macromolecules or epigenetic regulators (Goswami and Nakshatri, 2013). 
MiRNAs serve as diagnostic and prognostic biomarkers through the change of 
their level of expression by comparison between the normal and the cancer sample 
(Macha et al., 2014). Since the miRNAs are present in the body fluids such as 
saliva, serum, plasma and blood, their accessibility is facilitated.  
MiRNAs are used as biomarkers in various diseases including many cancers 
(Tricoli and Jacobson, 2007). It has been reported, through measuring the miRNA 
expression in non-cancerous and cancerous tissue collected from stage I–III 
squamous cell carcinoma (SCC) patients without any treatment prior to surgery, 
an association between high expression of miR-31 and poor survival of SCC were 
made (Cho, 2013).  Decreasing survival rates of patients with small-cell lung 
cancer is associated with high expression of miR-92a-2* (Cho, 2013). 
4.3 Predictive biomarker 
A predictive biomarker facilitates the monitoring of patients during treatment to 
measure the response of the patient to the specific treatment. Additional 
considerations may apply when evaluating the clinical utility of a predictive 
biomarker in selecting between two therapy options (Burke, 2016). The 
emergence of innovative technologies in Genomics, Proteomics, Metabolomics 
and imaging allows researchers to facilitate inclusive analysis of cancer cells. 
These approaches have already established its power to differentiate cancer cells 
from normal cells and to identify specific genetic elements involved in cancer 
(Nair, Sandhu and Sharma, 2014).  
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4.4 Using the available prognostic and expression databases. 
Several databases are available online to perform prognostic and expression 
analysis for miRNAs and their target genes. In this study some of these databases 
were utilised and are explained in the subsequent sections.  
4.4.1 MiRNA prognostic databases 
4.4.1.1 PROGmiRV2 database 
PROGmiR is a tool hosted within the PROGmiRV2 database, with the 
link http://www.compbio.iupui.edu/progmir. This tool can perform prognostic 
property analysis for a miRNA in various types of cancer using existing data from 
Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). This 
tool can be used to study overall survival implications for approximately 1050 
human miRNAs in 16 major cancer types (Goswami and Nakshatri, 2012). 
4.4.1.2 SurvMicro database 
The SurvMicro database is available at 
http://bioinformatica.mty.itesm.mx/SurvMicro,  is a curated and regularly updated 
online tool that provides information on miRNA expression and clinical outcome  
offering survival analysis and risk assessment in cancers (Aguirre-Gamboa and 
Trevino, 2014). Collection of data is performed using keywords related to cancer 
for searching clinical outcome, different miRNA platforms and 430 samples. The 
searches are performed in GEO, GEO Meta DB, Array Express, and TCGA 
(Aguirre-Gamboa and Trevino, 2014). 
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Gene target prognostic databases 
4.4.1.3 SurvExpress database 
SurvExpress is a database available at http:// 
bioinformatica.mty.itesm.mx/SurvExpress. It provides information about the 
validation of multi-gene biomarkers for clinical outcomes which is important to 
understand the monitoring of cancer prognosis. An important source of 
information for virtual validation is the high number of available cancer datasets 
(Aguirre-Gamboa et al., 2013). The datasets in SurvExpress are collected from 
Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) 
(Aguirre-Gamboa et al., 2013). At the input page, a list of genes identifier and a 
specific dataset can be chosen as specified by the user. SurvExpress uses two 
methods to generate risk groups. The first method (default) generates the risk 
groups splitting the ordered prognostic indices (higher values for higher risk) by 
the number of risk groups leaving an equal number of samples in each group 
(Aguirre-Gamboa et al., 2013). Secondly, to produce risk groups using an 
optimisation algorithm from the ordered prognostic index (PI). 
The outcome results of the database include common measures and plots such as 
box plots of gene expression across gene groups together with the p-value of the 
corresponding difference, risk group optimisation plot including a visual 
association of available clinical information to risk groups was used to assess the 
performance of the survival data (Aguirre-Gamboa et al., 2013). The database 
includes 20,000 cancer samples dispersed over 140 datasets covering more than 
20 tissues or types of cancer (Aguirre-Gamboa et al., 2013). 
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4.4.1.4 PrognoScan 
PrognoScan available at http://www.compbio.iupui.edu/proggene/ identifies 
prognostic biomarkers for several cancer types. This tool was designed to generate 
Kaplan-Meier plots for the genes that the user inputs (Goswami and Nakshatri, 
2013). The tool was generated by collecting publicly available data from 
repositories such as Gene Expression Omnibus (GEO), EBI Array Express and 
recently developed 'The Cancer Genome Atlas‟ (TCGA), PrognoScan has  64 
datasets for 18 different types of cancer, with this tool being the most 
comprehensive prognostic biomarker identification tool to date (Goswami and 
Nakshatri, 2013). The data outputs are provided as different graphical results such 
as expression plots, expression histograms, P-value plots and Kaplan-Meier plots 
as well as an annotation table (Mizuno et al., 2009). 
4.4.2 MiRNA and gene target expression databases 
4.4.2.1 Database of differentially expressed miRNAs in human cancers 
(dbDEMC version 2.0) 
DbDEMC version 2.0 is a database that can be accessed at 
http://www.picb.ac.cn/dbDEMC/index.html which is a significantly expanded 
version. The latest version of dbDEMC 2.0 contains expression data on 2224 
miRNAs across 36 cancer types through the processing of 200+ expression data 
sets. In this version, the volume of data has increased with the search and browser 
functions retained and improved as well as new features being added. This version 
of the database simplifies the identification of cancer associated miRNAs and a 
more in depth investigation of their roles in physiological and pathological 
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processes of cancer development (Yang et al., 2017). Also, miRNA-seq from 
TCGA was included in dbDEMC 2.0 which is composed high quality miRNA 
expression profiles for 22 type of cancers and more than 400 data sets were 
collected initially (Yang et al., 2017). 
The new version of dbDEMC 2.0 includes 209 miRNA expression data sets from 
143 peer-reviewed publications and those from TCGA. Presently it holds 49202 
miRNA–cancer associations for 2224 differentially expressed miRNAs identified 
from 436 experiments, and a total of 36 cancer types and 73 cancer subtypes are 
covered. Also, it includes 86% of the miRNAs identified in the human genome 
from miRBase Release 21, which is the total number of differentially expressed 
miRNAs. 
Meta-profiling analysis added to dbDEMC 2.0 as new function allows users to 
perform expression profiling to demonstrate the expression of miRNAs among a 
specific set of cancer types. A list of miRNAs can be used as input, and one of the 
six types of experimental designs can be selected as well as the cancer type of 
interest. The meta-profiling analysis generates a heat-map describing the 
expression change for the inquired miRNA across multiple cancer types. The up 
and down-regulated expression status of a miRNA is classified by red and green 
colours respectively according to a confidence score, which is calculated based on 
studies of each specific cancer type and experimental evidence supporting the 
differential expression status (Yang et al., 2017). 
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4.4.2.2 FIREBROWSE database for gene expression analysis 
FIREBROWSE is accessed at http://firebrowse.org underlined by a powerful 
computational infrastructure, application programming interface (API), graphical 
tools and online reports. Graphical tools like viewGene to explore expression 
levels, and iCoMut to explore the comprehensive analysis profile of each TCGA 
disease studied within a single, interactive figure are novel features of this portal. 
To date it is one of the most integrative open access cancer datasets with over 80K 
sample aliquots from 11,000+ cancer patients, spanning 38 unique disease 
cohorts. Using FIREBROWSE, TCGA data and analysis in cBioPortal-
expression, mutation, copy number, significance analysis, and other operations 
can be loaded directly (FIREBROWSE, 2016). All tissues utilized by the database 
in their abbreviated form are shown in table 4.1   
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Table 4. 1: List of abbreviation used in graphical result from the FIREBROWSE 
database 
ACC Adrenocortical 
carcinoma 
SARC Sarcoma  
BLCA Bladder Urothelial 
carcinoma 
STES Stomach and 
esophageal carcinoma 
BRCA Breast invasive 
carcinoma 
PRAD Pancreatic 
adenocarcinoma 
CESC Cervical squamous cell 
carcinoma and 
endocervical 
adenocarcinoma 
UCS Uterine 
Carcinosarcoma  
CHOL Cholangiocarcinoma KIRC Kidney renal clear cell 
carcinoma  
COAD Colon adenocarcinoma  KIPAN Pan-kidney cohort 
COADREAD Colorectal 
adenocarcinoma 
THCA Thyroid carcinoma  
DLBC Lymphoid neoplasm 
Diffuse large B-cell 
Lymphoma 
SKCM  Skin cutaneous 
Melanoma 
ESCA Esophageal carcinoma LGG Brain lower grade 
glioma  
LUSC Lung squamous cell 
carcinoma 
GBMLGG Glioma  
OV Ovarian serous 
cystadenocarcinoma 
GBM Glioblastoma 
multiforme 
PRAD Prostate 
adenocarcinoma 
THYM Thymoma  
MESO Mesothelioma  PCPG Pheochromocytoma 
and Paraganglioma  
KICH Kidney Chromophobe  HNSC Head and neck 
squamous cell 
carcinoma  
LIHC Liver hepatocellular 
carcinoma  
KIRP Kidney renal papillary 
cell carcinoma  
TGCT Testicular germ cell 
tumour  
READ Rectum 
adenocarcinoma  
UCEC Uterine Corpus 
endometrial carcinoma  
UVM Uveal Melanoma  
STAD Stomach 
adenocarcinoma  
LAML Acute Myeloid 
Leukaemia 
LUAD Lung adenocarcinoma    
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4.5 Aim and objectives 
The aim of this chapter was to perform prognostic and predictive analysis of the 
five miRNAs and their target genes using various in silico databases as well as 
expression analysis of these miRNAs and their target genes 
I. Perform prognostic analysis for the five miRNAs using the PROGmiRV2 
and SurvMicro databases;  
II. Perform prognostic analysis for the miRNAs target genes using the 
SurvExpress and PognoScan databases;  
III. Perform in silico expression analysis for the miRNAs using dbDEMC 2.0; 
and  
IV. Perform in silico expression analysis for miRNAs target genes using 
FIREBROWSE database.  
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4.6 Methods and Materials 
Prognostic and expression analysis was performed on the five miRNAs and their 
12 target genes using the available online databases namely, PROGmiR, 
SurvMicro, SurvExpress, PrognoScan, dbDEMC 2.0 and FIREBROWSE. 
4.6.1 Databases for miRNAs and target genes prognostic analysis   
4.6.1.1 PROGmiRV2  
ProgmiR was accessed at http://xvm145.jefferson.edu/progmir/ and was used for 
the prognostic analysis of the five miRNAs. All five miRNA names were 
submitted together as input. For the cancer type “prostate adenocarcinoma” was 
selected, and for survival measure, “death” was selected and a positive control 
miRNA was also submitted to confirm the performance of the database. 
4.6.1.2 SurvMicro database 
SurvMiro was accessed at http://bioinformatica.mty.itesm.mx/SurvMicro and the 
five miRNAs was used as input to examine the prognostic value for these 
miRNAs. All miRNA names were pasted in the query box with the following 
steps followed before analysis, (i) “prostate tissue” was selected from the tissue 
option; (ii) “prostate adenocarcinoma TCGA” database was selected which 
included 126 samples; and (iii) under the duplication option two setting were 
selected, (a) “show all” and (b) data “original. The Cox survival analysis test 
setting was applied for “censored” data: Survival-months were selected and for 
“stratification” class, GLEASON was selected. 
http://etd.uwc.ac.za/
84 
 
4.6.1.3 SurvExpress database 
SurvExpress accessed at 
http://bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp was used to 
evaluate the prognostic value(s) of the 12 miRNA target genes in PCa patient and 
the following steps were followed: (i) a list of gene identifiers were used as input 
into the “query” option; (ii) SurvExpress incorporates eight databases and TCGA 
was selected, as it houses the largest number of samples equalling to 497, (iii) 
under the duplication option two settings were selected, (a) “show all” and (b) 
data “original. Cox Survival Analysis was applied with censored data set to 
survival-days. 
4.6.1.4 PrognoScan 
PrognoScan was accessed at http://www.abren.net/PrognoScan/ to perform the 
prognostic analysis for the miRNA target genes by submitting each gene 
individually into the “query” option. From the list of different cancers provided, 
“prostate cancer” was selected. The results for this database were given as a 
Kaplan Meier plot. 
4.6.2 Databases miRNAs and target genes expression analysis 
4.6.2.1 DbDEMC 2.0 miRNA expression analysis 
The DbDEMC 2.0 database was accessed at http://www.picb.ac.cn/dbDEMC/  
and was used to evaluate the expression of the five miRNAs in blood for PCa. The 
list of five miRNAs was pasted within the query box indicated as “miRNAs list” 
on the home page and for the experimental design section “blood” was selected 
http://etd.uwc.ac.za/
85 
 
and for the cancer type “prostate cancer” was selected to generate a heat map for 
the expression profiling of the miRNAs. 
4.6.2.2 FIREBROWSE database 
The FIREBROWSE was accessed at http://firebrowse.org/. First “prostate 
adenocarcinoma” (PRAD) was selected in the cohort section. Secondly, the gene 
names were submitted individually into the query box option, with view 
expression profile selected afterwards and the expression sorted from high to low 
expression. 
4.7 Results  
4.7.1 Databases for miRNA prognostic analysis 
PROGmiRV2 and SurvMicro databases  
All five miRNAs were submitted to PROGmiR and SurvMicro databases and no 
results were obtained from these databases. Considering that these miRNAs 
showed no association with PCa as observed in Chapter 2, the results observed 
here strengthens the notion that these miRNAs are potentially novel for PCa. One 
miRNAs was used as positive control and the graphical result shown in figure 4.1.  
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Figure 4.1: Kaplan Meier plot for positive control miRNA generated by the 
PROGmiRV2 database. 
4.7.2 SurvExpress database 
The list of miRNA target genes was submitted to SurvExpress for prognostic 
analysis and the results were displayed for the genes and their associated risk 
groups based on their individual expression levels. Results for all the genes were 
obtained as shown in figure 4.2 Results output were represented as box plots 
indicating the expression levels of genes and risk groups. From the box plots, it 
was assessed whether gene expression levels differed between the high-risk (red) 
and low-risk groups (green) as well as the level of significance of expression (p-
value < 0.05) using a t- test. The results indicate genes IGF1, PTGS2, SRD5A2, 
CYP24A1, AMACR, AR, NKX3-1, MYH11, and KLK4 showing a distinct 
difference between the low and the high-risk groups. The difference in expression 
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between risks groups for these genes can be useful for prognostic outcomes for 
PCa, i.e. whether a patient‟s survival is affected by the expression of these genes. 
 
Figure 4.2: Gene expression analysis of the microRNA target genes using 
SurvExpress. The result outputs are given as box plots showing the expression of 
the gene in low and high-risk groups. 
4.7.3 PrognoScan Results 
Twelve genes were submitted to PrognoScan for the prognostic analysis as 
explained in subsection 4.6.1.4. Eleven out of the 12 genes showed link to PCa 
with one gene not showing any link to PCa in PrognoScan. Three genes (IGF-1, 
KLK3, and KLK4) showed significant Cox p-values 0.003233, 0.001101 and 
0.040085, respectively as shown in figure 4.3 for the Kaplan Meier plot results for 
these genes as well as within the annotation tables (see Appendix B table 4. A, B, 
and C). Thus, it implies that these three genes either individually or in 
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combination has good dicriminatory value between high-risk and low-risk PCa 
groups, making them potentially useful biomarkers in the management of PCa. 
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IGF1 
 
KLK3 
 
 
KLK4 
 
 
Figure 4.3: Kaplan Meier plots for IGF1, KLK3, and KLK4, showing their levels 
of expression for the high risk groups in red and for the low risk groups in blue 
use the PrognoScan database. 
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4.7.4 Expression analysis of potential MiRNAs  
All five miRNAs were submitted to dbDEMC 2.0 for their expression analysis in 
blood extracted from PCa patient with no results shown from this database which 
imply that these miRNAs are potentially novel for their association with PCa. 
4.7.5 Result from FIREBROWES database 
The list of miRNA target genes identified in chapter 3 was submitted to 
FIREBROWES for gene expression analysis in 37 cancers. In Figure 4.4, the 
expression of AR in all cancer types is shown. It is notable that the AR gene 
expression is higher in the normal prostate tissue compared to prostate cancer 
tissue but in general is expressed in normal prostate and prostate tumour  tissue 
compare to the among 37 analysed (BRCA, OV, KIRC, LIHC, KIPAN, KIRP, 
UCEC, GBM, GBMLGG, LGG, SARC, PAAD, LAML, KICH, CHOL, LUAD, 
THCA, UCS, STAD, BLCA, TGCT, STES, ACC, ESCA, LUSC, MESO, HNSC, 
PCPG, CESC, READ, COADREAD, COAD, SKCM, UVM, THYM, DLBC). 
In Figure 4.5, illustrate the expression of IGF1 in the 37 cancer types and was 
highly differentially expressed in ovarian serous cystadenocarcinoma (OV) 
followed by PRAD. All the other cancer types showed lower expression when 
compared to PRAD. When comparing between the normal tissue and prostate 
tumour tissue, expression was lower in the tumour tissue as indicated by the red 
colour. 
 
In Figure 4.6, KLK3 is notably over-expressed in both normal prostate tissue and 
prostate tumour tissue followed by kidney chromophobe (KICH) when compared 
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to the other cancer tissues. It is expressed higher in prostate tumour tissue than 
within normal prostate tissue. 
 
In Figure 4.7, the highest expression for KLK4 is observed in normal and tumour 
prostate tissue compared to the 37 normal and tumour tissues analysed. KLK4 was 
highly expressed in tumour tissue when compared to normal prostate tissue. 
 
In Figure 4.8, KLK2 was highly expressed in prostate tissue compared to the other 
37 normal prostate tissues with its highest expression in prostate tumour tissue.  
 
AMACR showed the highest expression in the kidney renal papillary cell 
carcinoma (KIRP) tissue followed by its second highest expression in normal 
prostate tissue and prostate tumour tissue, as shown in Figure 4.9. 
 
CYP24A1 shows high expression in the following 9 normal and tumour  tissues 
(LUAD, HNSC, KIRP, CESC, LUSC, KIPAN, UCEC, UCS) followed by 
prostate normal and prostate tumour tissue, as shown in figure 4.10. 
 
MYH11 showed high expression in prostate tumour and normal tissue when 
compared to all other normal and tumour tissue as shown in figure 4.11 followed 
by stomach adenocarcinoma (STAD) tissue. 
 
NKX3-1 show high expression in normal prostate tissue and prostate tumour tissue 
when compared to the 37 tissues analysed, as shown in Figure 4.12 followed by 
http://etd.uwc.ac.za/
92 
 
adrenocortical carcinoma (ACC).  NKX3-1 was over-expressed in prostate tumour 
tissue when compared to normal prostate tissue. 
 
PTGS2 is over-expressed in LUAD, BLCA, LUCS, LAML, HNSC, and PRAD 
tissues, as shown in Figure 4.13, with PTGS2 showing a higher expression in 
normal prostate tissue when compared to prostate tumour tissue. 
 
SRD5A2 showed high expression in prostate tumour tissue compared to the other 
37 tumour tissues with its expression down-regulated in prostate tumour tissue 
when compared to normal prostate tissue, as shown in Figure 4.14. 
 
TMPRSS2 shows a high expression in prostate tumour tissue when compared to 
the other 37 tumour tissues with a higher expression in prostate tumour tissue 
compared to normal prostate tissue as shown in Figure 4.15. 
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Figure 4.4: Show the expression of the AR gene in 37 cancers types with 
expression sorted from high to low. 
 
Figure 4.5: Show the expression of the IGF1 gene in 37 cancers types with 
expression sorted from high to low 
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Figure 4.6: Show the expression of KLK3 in 37 different cancer types sorted from 
high to low expression. 
 
Figure 4.7: Show the expression of KLK4 in 37 different cancer types sorted from 
high to low expression. 
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Figure 4.8: Show the expression of KLK2 in 37different cancer types sorted from 
high to low expression 
 
Figure 4.9: Show the expression of AMACR in 37 different tumour and normal 
tissues sorted from high to low expression 
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Figure 4.10: Show the expression of CYP24A1 in 37 different tumour and normal 
tissues sorted from high to low expression 
 
Figure 4.11: Show the expression of MYH11 in 37 different tumour and normal 
tissues sorted from high to low expression 
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Figure 4.12: Show the expression of NKX3-1 in 37 different tumour and normal 
tissues sorted from high to low expression 
 
Figure 4.13: Show the expression of PTGS2 in 37 different tumour and normal 
tissues sorted from high to low expression 
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Figure 4.14: Show the expression of SRD5A2 in 37 different tumour and normal 
tissues sorted from high to low expression 
 
Figure 4. 15: Show the expression of TMPRSS2 in 37 different tumour and 
normal tissues sorted from high to low expression 
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4.8 Discussion  
Prostate cancer is one of the leading causes of death and the number of new case 
are increasing rapidly (Pakzad et al., 2015). Cancer biomarkers can provide 
information with regard to the cancer stage of diagnosis, progression as well as a 
predictive indicator pre- and post-treatment (Richard Mayeux, 2004). MicroRNAs 
can be used as a prognostic biomarker for different types of cancer by 
investigating the expression of the microRNA at a different stage of cancer, and 
calculating cancer patient survival rates based on these expression changes (Yang 
et al., 2016). Prognostic biomarkers aid in detecting molecular alterations in 
expression assisting in development of new therapeutic strategies based on the 
risk of the progression of cancer (Mancarella et al., 2017a). 
 
In this work, five miRNAs were identified in chapter 2 and their target genes 
identified in chapter 3. In particular, the miRNAs, as well as their target genes are 
evaluated for their prognostic value in PCa using an in silico approach.  
 
Prognostic and expression analysis of the miRNAs 
First, the five miRNAs were submitted to two prognostic databases which are 
(PROGmiR and MicroSurv) and one expression database dbDEMC version 2.0.  
No results were obtained for these miRNAs. These miRNAs showed no links to 
PCa as evident from the literature mining in chapter 2. Thus, the result obtained 
here lends more credence to these miRNAs being potentially novel for PCa. 
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Prognostic and expression analysis of the miRNA target genes 
Secondly, a list of the miRNA target genes was submitted to the SurvExpress  
database to examine the prognostic value for these genes. The results dobtained is 
indicated by the graph in figure 4.2 which shows the expression of these genes for 
the high and low-risk PCa groups with their respective p-values indicated. Nine 
genes namely IGF1, PTGS2, SRD5A2, CYP24A1, AMACR, AR, NKX3-1, MYH11, 
and KLK4 is able to differentiate the high-risk group from the low-risk group for 
PCa however, not statistically significantly so for all of these nine genes.  
 
Epidemiological studies have reported that high serum IGF-1 concentration and 
decreased circulating IGFBP-3 are correlated with an increased risk of developing 
PCa which can be interpreted as IGF-1 having good prognostic value for PCa 
(Chan et al., 1998; Mancarella et al., 2017a).  
Previous study showed that the Insulin-like Growth Factor (IGF) system is 
influenced by TMPRSS2 as ERG (a transcription factor), directly binds the IGF-
1R gene promoter, thus affecting its expression in PCa. In another study, it was 
shown that patients with PCa that do not harbour the TMPRSS2-ERG 
rearrangement and who express low levels of IGF-1R, represent a subgroup of 
primary PCa tumours with poor outcome (Meisel-Sharon et al., 2016; Mancarella 
et al., 2017b). 
Another study has identified PTGS2 rs4648302 as a prognostic predictor for PCa. 
This variant might alter miRNA binding and thus influences PTGS2 expression 
and PCa progression. Clinical studies have suggested that selective PTGS2 
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inhibitors could reduce cancer risk. If validated, this knowledge could ultimately 
lead to targeted therapies for a subset of high-risk patients harbouring this 
inherited PTGS2 variant (Reddy et al., 2000; Smith et al., 2006; Lee et al., 2016). 
SRD5A 1 and 2, are the two enzymes that catalyse the transformation of 
testosterone to dihydrotestosterone (Audet-Walsh et al., 2017). Interrogation 
of SRD5A mRNA expression in three publicly available datasets confirmed 
that SRD5A1 is increased in primary and metastatic PCa compared with non-
tumoural prostate tissues, whereas SRD5A2 is decreased. Activation of the 
androgen receptor (AR), a major oncogenic driver of PCa, induced the expression 
of SRD5A1 from twofold to fourfold in three androgen-responsive PCa cell lines 
(Audet-Walsh et al., 2017). Previously it has been suggested that increase in DNA 
methylation of SRD5A2 and CYP11A1 detectable in plasma have prognostic 
values for non-invasive PCa by monitoring biochemical recurrence after radical 
prostatectomy (Horning et al., 2015). 
 
CYP24A1 mRNA was higher in malignant human prostate tissues compared to 
benign lesions. High CYP24A1 protein levels were seen in poorly differentiated 
and highly advanced stages of PCa and correlated with a parallel increase in the 
tumour proliferation rate (Tannour-Louet et al., 2014). According to a study, AR 
signalling has reported as essential for the growth and maintenance of the prostate 
as well as the initiation and progression of PCa (Blessing et al., 2017). 
 
It has been reported that NKX3.1 works as a prostatic tumour suppressor gene. 
Studies have showed positive results for the staining of the NKX3.1 protein in 
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most of primary prostatic adenocarcinomas. This protein has been found down-
regulated in many high-grade PCa and completely lost in most of metastatic PCa 
(Gurel et al., 2010). In another study, the sensitivity and specificity of NKX3.1 in 
high-grade prostatic adenocarcinoma when stained with a novel antibody when 
compared with high-grade urothelial carcinoma (Gurel et al., 2010). It has also  
been reported that NKX3.1 correlates with PCa progression (Bowen et al., 2000). 
 
The expression of KLK4 show association with an increased PCa risk, and its 
activity favours tumour progression through increasing cell motility and growth. 
Notably, increasing KLK4 expression in prostate glandular cells promotes tumour 
development, positioning the enzyme to play a role in early remodelling of the 
tumour microenvironment, a process essential for tumour growth (Kryza et al., 
2017). 
 
The results from PrognoScan aligned with SurvExpress for two genes namely 
IGF1 and KLK4 which in both databases showed highly significant prognostic 
value. Also, the results showed good prognostic value for KLK3 as shown in 
figure 4.2 in the Kaplan Meier plots. 
Expression analysis using FIREBROWES showed the the expression of the 
miRNA target genes by comparing the expression of each gene across 37 tumour 
tissues see figures 4.4 to 4.15. 
Eight out of 12 genes  namely AR, CYP24A1, KLK2, KLK3, KLK4, MYH11, 
NKX3.1, and TMPRSS2 was found to be differentially expressed in pancreatic 
adenocarcinoma (PRAD) with a high specificity for PRAD when compared to 
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other cancerous tissues. Moreover, four out of these eight genes NKX3.1, KLK4, 
CYP24A1, and AR showed good prognostic value using the SurvExpress database. 
 
Taken together no results were obtained for the five miRNAs when their 
prognostic value was investigated using the PROGmiRV2 and SurvMicro 
databases. Also, in the expression analysis using dbDEMC 2.0 no expression 
results were obtained for the miRNAs, the notion is thus strengthened that these 
are potentially novel for PCa. The prognostic analysis of the 12 miRNA targeted 
genes showed good prognostic value for five out of the 12 genes with clear 
implications of these genes in PCa as observed from the literature. In addition, 8 
of the target genes shows differential expression in PCa with four of these genes 
showing good prognostic value to differentiate high risk and low risk PCa groups. 
Thus, the miRNAs that regulate these genes can indirectly be linked to PCa in the 
absence of molecular validation data for these miRNAs. 
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Chapter 5 
Conclusion and future work 
5.1 Introduction  
Prostate cancer is the most common cancer in man and can be treated if diagnosed 
in its early stages. Only in South Africa the incidences of PCa in 1995 were 
reported as 2 504 cases and after 10 years, in 2005, 4 631 new cases were 
reported. Over a 20-year time period from 1986 to 2006, 63 886 PCa cases were 
reported to the National Cancer Registry (NCR) (Babb et al., 2014). The highest 
numbers of incidences were reported in the white population group within South 
Africa (Babb et al., 2014). Relatively small numbers were noticed within the 
coloured and Asian/Indian population groups. Both the black and white 
population groups had fairly consistent numbers being reported throughout the 
years, in particular, for the last 5 years of reporting (Babb et al., 2014). Current 
diagnostic tools for PCa include prostate specific antigen (PSA), Digital Rectal 
Examination (DRE), Magnetic Resonance Imaging (MRI) Computed tomography 
(CT) and Prostate biopsy which all have limitations such as lack of sensitivity and 
specificity, some of these methods carry high costs, report false-negative and 
false-positive results and are also invasive (Heidenreich et al., 2011; Alberts et al., 
2017). The need for new biomarkers to facilitate the processes of diagnosis of PCa 
has become an important step for PCa management with miRNAs emerging as 
worthwhile molecules to investigate for this purpose. 
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MiRNAs have been found in the body fluids such as serum, plasma, urine, and 
saliva, which is an easily accessible alternative for invasive biopsy procedures 
(Lan et al., 2015). 
The first discovery of small non-coding RNA (microRNAs) was in 1993 
(Almeida, Reis and Calin, 2011). They function in regulating mRNA producing 
proteins that are involved in the biological processes, such as apoptosis, cell 
proliferation, thus implicating miRNAs within these processes as well.  
MicroRNAs show potential use as diagnostic, prognostic and therapeutic 
resolutions for different cancers including PCa. Therefore, the main aim of this 
study was to identify novel microRNAs as biomarkers for the early stage 
detection of PCa using several in silico methods. The advantage of using an in 
silico approaches is that it is rapid, cost-effective, and less labour intensive.  
5.2 Chapter 2 
Identification of novel miRNAs involved in PCa 
The aim in this chapter was to identify novel miRNAs involved in PCa for 
diagnostic and prognostic purposes. This was achieved by using the CD-HIT 
program and BLAST. Two lists of miRNAs were generated one from Exiqon 
which contained 156 miRNAs experimentally validated to be involved in PCa and 
a second list, which contained 2588 mature miRNA sequences. Using the CD-HIT 
program and BLAST as described in sections, 16 miRNAs were identified with a 
potentially novel association with PCa. This list was refined to only five miRNAs 
through literature mining, which showed no association to PCa 
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5.3 Chapter 3 
 
Identification of the miRNA target genes  
The aim in this chapter was to identify the target genes of these potentially novel 
miRNAs for PCa. Furthermore, we confirmed the implication of these genes in 
PCa through various in silico analyses. By doing so, the miRNAs can indirectly 
be linked to PCa in the absence of molecular data for these molecules. 
A list of target genes was identified using the mirDIP database as well as a list of 
all genes implicated to be expressed in prostate tissue was generated using the 
TiGER database. The intersection between these two lists was determined using 
Venn diagrams resulting in 212 genes targeted by the five miRNAs. Through 
functional annotation using the DAVID database as described in section, this 
number was reduced to 12 unique genes KLK3, KLK2, KLK4, AR, CYP24A1, 
AMACR, NKX3.1, TMPRSS2, SRD5A1, PTGS2, MYH11, and IGF1. Using a 
combination of pathway analysis utilizing the KEGG pathway tool as well as 
protein-protein interaction analysis using STRING, these genes were implicated 
further in cancer pathways and specifically in PCa onset and progression 
pathways. 
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5.4 Chapter 4  
Prognostic and expression analysis of the miRNA target genes 
Both the miRNAs and their target genes were analysed for their prognostic value 
for PCa using several in silico tools. In addition, the expression of the miRNAs 
and their target genes were analysed in various tumour tissues as well as normal 
tissues using several in silico databases. For the miRNAs none of the prognostic 
or the expression databases showed any results to implicate these miRNAs in 
PCa. This result furthers the notion that these miRNAs are novel for PCa, since 
the databases utilised are based on experimental evidence to implicate existing 
miRNA in different disease processes including cancer. 
For the prognostic evaluation of the miRNA target genes, 11 out of the 12 genes 
showed a fair to very good prognostic value for PCa based on the expression of 
these genes within high- and low-risk groups for PCa survival. Through 
expression analysis 8 out of the 12 genes showed differential expression between 
prostate tumour tissue and normal prostate tissue, with the expression for some of 
these genes specific for prostate tumour tissue. 
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Table 5.1: Show genes that are involved in PCa pathways, genes having 
prognostic value and genes that are expressed in prostate tumour tissue. 
Pathway analysis Prognostic analysis Expression analysis 
AR AR AR 
NKX3-1 NKX3-1 NKX3-1 
KLK3 KLK4 KLK3 
IGF1 IGF1 KLK2 
 AMACR KLK4 
 CYP24A1 MYH11 
 MYH11 CYP24A1 
 PTGS2 TMPRSS2 
 SRD5A2  
 
5.5 Conclusion 
In this thesis five potentially novel miRNAs were identified that could be used for 
diagnostic as well as prognostic purposes for the management of PCa. These five 
miRNAs regulates 12 genes of which 11 was showed to have marginal to strong 
prognostic value for PCa with eight genes showing differential expression for 
prostate tissue compared to normal prostate tissue as well as other cancerous 
tissue. Thus, following molecular validation, both the miRNAs as well as their 
target genes can be utilised as biomarkers for PCa diagnosis as well as prognosis. 
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5.6 Future work 
Follow-up work includes the expression profiling of the miRNAs in cell lines as 
well as clinical samples, using RT-qPCR to confirm their specificity and accuracy 
for PCa diagnosis. Additionally, to validate the genes that are regulated by these 
miRNAs using a luciferase assay which will determine the effect of these 
miRNAs on the functioning of their target genes. Other molecular diagnostic 
techniques such as fluorescent in situ hybridization (FISH), which is a cytogenetic 
technique to detect the location of specific gene or specific nucleic acid sequence 
on chromosomes, can be employed. In addition, the copy number of genes and 
expression profiles of microRNAs can be assessed to differentiation between 
normal and cancer PCa tissue using Next Generation Sequencing (NGS). Deep 
sequencing technologies have the advantage to detect novel sequences, that could 
be used to determine the function of microRNAs in PCa since the advantage of 
using these techniques is they have high accuracy and specificity for miRNA 
detection the normal versus cancer tissue. 
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Appendix A 
Supplementary table for chapter 2 
Table A.1: list of validated miRNAs in prostate cancer with their reference  
MiRNAs name Accession number                                                 References
hsa-let-7a-3p MIMAT0004481 Wang M. et al., 2011 
hsa-let-7a-5p MIMAT0000062 Wang M. et al., 2011 
hsa-let-7b-5p MIMAT0000063 Liu C. et al., 2012 
hsa-let-7c-5p MIMAT0000064 Chen Z. H. et al., 2012 
hsa-let-7d-5p MIMAT0000065 Ramberg H. et al., 2011 
hsa-let-7e-5p MIMAT0000066 Chen Z. H. et al., 2012 
hsa-let-7g-5p MIMAT0000414 Prueitt R. L. et al., 2008 
hsa-miR-1 MIMAT0000416 Liu Y. N. et al., 2013 
hsa-miR-100-5p MIMAT0000098 Leite K. R. et al., 2011 
hsa-miR-101-3p MIMAT0000099 Hao Y. et al., 2011 
hsa-miR-101-5p MIMAT0004513 Hao Y. et al., 2011 
hsa-miR-106a-5p MIMAT0000103 Liu C. et al., 2012 
hsa-miR-106b-5p MIMAT0000680 Hudson R. S. et al., 2012 
hsa-miR-107 MIMAT0000104 Bryant R. J. et al., 2012 
hsa-miR-10a-5p MIMAT0000253 Prueitt R. L. et al., 2008 
hsa-miR-10b-5p MIMAT0000254 Prueitt R. L. et al., 2008 
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Appendix B 
Supplementary table for chapter 4 
Table 4.A:  Annotation table for IGF1 from PrognoScan database 
DATA 
POSTPROCESSING 
None 
PROBE_NAME DAP3_5880 [6K DASL] 
PROBE_DESCRIPTION insulin-like growth factor 1 (somatomedin C) 
GENE_SYMBOL IGF1 
GENE_DESCRIPTION insulin-like growth factor 1 (somatomedin C) 
DATASET GSE16560 
CANCER_TYPE Prostate cancer 
SUBTYPE  
N 281 
ENDPOINT Overall Survival 
PERIOD Months 
COHORT Sweden (1977-1999) 
ARRAY TYPE 6K DASL 
CONTRIBUTOR Sboner 
SAMPLE 
PREPARATION 
DASL 
CUTPOINT 0.40 
MINIMUM P-VALUE 0.000219 
CORRECTED P-VALUE 0.006963 
ln(HRhigh / HRlow) -0.52 
COX P-VALUE 0.003233 
ln(HR) -0.26 
HR [95% CI] 0.77 [0.64 - 0.92] 
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Table 4.B: Annotation table for KLK4 from Prognoscan database 
DATA 
POSTPROCESSING 
None 
PROBE_NAME DAP2_0881 [6K DASL] 
PROBE_DESCRIPTION kallikrein-related peptidase 4 
GENE_SYMBOL KLK4 
GENE_DESCRIPTION kallikrein-related peptidase 4 
CANCER_TYPE Prostate cancer 
SUBTYPE  
N 281 
ENDPOINT Overall Survival 
PERIOD Months 
COHORT Sweden (1977-1999) 
ARRAY TYPE 6K DASL 
CONTRIBUTOR Sboner 
SAMPLE 
PREPARATION 
DASL 
CUTPOINT 0.39 
MINIMUM P-VALUE 0.007654 
CORRECTED P-
VALUE 
0.131774 
ln(HRhigh / HRlow) -0.38 
COX P-VALUE 0.040851 
ln(HR) -0.28 
HR [95% CI] 0.76 [0.58 - 0.99] 
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Table 4.C: Annotation table for KLK3 from PrognoScan database 
DATA 
POSTPROCESSING 
None 
PROBE_NAME DAP1_1066 [6K DASL] 
PROBE_DESCRIPTION kallikrein-related peptidase 3 
GENE_SYMBOL KLK3 
GENE_DESCRIPTION kallikrein-related peptidase 3 
DATASET GSE16560 
CANCER_TYPE Prostate cancer 
SUBTYPE  
N 281 
ENDPOINT Overall Survival 
PERIOD Months 
COHORT Sweden (1977-1999) 
ARRAY TYPE 6K DASL 
CONTRIBUTOR Sboner 
SAMPLE 
PREPARATION 
DASL 
CUTPOINT 0.62 
MINIMUM P-VALUE 0.088109 
CORRECTED P-
VALUE 
- 
ln(HRhigh / HRlow) -0.25 
COX P-VALUE 0.001101 
ln(HR) -1.15 
HR [95% CI] 0.32 [0.16 - 0.63] 
 
http://etd.uwc.ac.za/
